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Abstract 
Dietary fibers are a broad subset of non-digestible carbohydrates that have many health 
benefits to consumers. When consumed in adequate amounts they can protect against 
cardiovascular disease, decrease the risk of diabetes, aid in weight loss and numerous 
other health benefits. One unique attribute that dietary fibers have is that when they reach 
the distal intestine or colon, some of these fibers can be fermented by the hundreds of 
species of bacteria present. When these fibers provide growth to the beneficial bacteria 
present in the gastrointestinal tract, they are referred to as prebiotics, or prebiotic dietary 
fibers. As the understanding of the gut micobiota and the gut microbiome expand, the 
importance of stimulating the beneficial microbiota present in the gut becomes 
increasingly more important. Because the human diet is so complex, understanding the 
fermentation process of individual compounds can be a difficult task.  
 
The use of in vitro fermentation models is one way to understand the fermentation of 
dietary fibers, and whether or not they support the growth of beneficial taxa, and very 
closely mimics the function of the colon in that regard. Incubating fecal bacteria from 
human donors, exposing them to specific dietary fibers, and measuring their fermentation 
differences provides a snapshot of how these compounds may ferment in vivo. The 
primary objective of this research was to conduct a preliminary in vitro analysis of two 
emerging dietary fibers (wheat dextrin and partially hydrolyzed guar gum) to test their 
prebiotic capacity (Chapter 2), and to compare new dietary fibers (Oatwell, 
xylooligosaccharides, beta-glucans) to an established prebiotic dietary fiber (inulin) to 
   vii
measure key fermentation differences in vitro (Chapter 5). The secondary objective of 
this research was to compare fermentation differences between donors exposed to these 
same compounds by measuring differences in the production of short chain fatty acids 
(Chapter 3), and the microbiota that were stimulated (Chapter 4). The final objective of 
this research was to determine if conventionally or organically grown plants in Minnesota 
provided a significant amount of dietary fiber, if it was fermentable, and whether or not 
the growing differences in these plants affected key nutrients and compounds, including: 
vitamin C, potassium, iron, sodium, calcium and nitrate-nitrogen.  
 
Both wheat dextrin and partially hydrolyzed guar gum stimulated growth of two 
beneficial genera of bacteria, Lactobacillus and Bifidobacterium, indicating that both 
fibers are bifidogenic and lactogenic within 24 h of fermentation (Chapter 2). At 12 h 
wheat dextrin was significantly more bifidogenic (9.50 CFU log10/mL) than partially 
hydrolyzed guar gum (PHGG) (9.30 CFU log10/mL) (p=0.052), and also at 24 h wheat 
dextrin (9.41 CFU log10/mL) compared with PHGG (9.27 CFU log10/mL) (p=0.043). 
Wheat dextrin produced less total short chain fatty acids at both 12 h and 24 h than 
partially hydrolyzed guar gum, and produced significantly lower amounts of gas at 12 h 
and 24 h (p<0.001, p<0.001), a key marker for gastrointestinal tolerance.   
 
Changes in short chain fatty acid concentration (SCFA) due to the fermentation of dietary 
fibers in the colon has been widely studied, but there are limited studies analyzing the 
differences in this production across multiple individuals (ages 23-68) exposed to the 
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same dietary fiber (Chapter 3). The objective of this project was to look at fermentation 
differences from six fecal donors all exposed to partially hydrolyzed guar gum in an in 
vitro model. With the six donors analyzed in this study, gas production varied from 59-80 
mL/0.5g fiber at 12 h and 85-93 mL/0.5g fiber at 24 h between the six donors. At 12 h 
butyrate concentrations varied from 6.99 µmol/mL to 23.84 µmol/mL and from 8.78 
µmol/mL to 22.84µmol/mL at 24 h. Total SCFA concentration at 24 h ranged from 42.85 
µmol/mL to 91.17 µmol/mL. With over a 2-fold difference in SCFA production, 
significant differences were found between healthy individuals exposed to partially 
hydrolyzed guar gum in vitro.  
 
Following this analysis, 16s rRNA sequencing was used to identify the fecal microbiota 
responsible for the fermentation of partially hydrolyzed guar gum (Chapter 4) comparing 
samples at baseline, 12 h and 24 h post-exposure. Parabacteroides increased from 3.48% 
of sequence reads to 10.62% of sequence reads after 24 h (p = 0.0181) and Bacteroidetes 
increased from 45.89% of sequence reads to 50.29% of sequence reads (p = 0.0008). 
Partially hydrolyzed guar gum stimulates growth of Parabacteroides, a genus of bacteria 
that have been inversely associated with irritable bowel syndrome (IBS) and ulcerative 
colitis. PHGG provides stimulation of beneficial Bacteroidetes (Bacteroides and 
Parabacteroides), which may be correlated with many positive health markers and 
outcomes in vivo.  
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Five other dietary fibers were analyzed to test their prebiotic capacity and fermentation 
differences, including: Oatwell, inulin, beta-glucan, xylooligosaccharide and a dried 
chicory root blend. Oatwell had the highest production of propionate at 12 h (4.76 
μmol/mL) compared to inulin, dried chicory root blend and xylooligosaccharide samples 
(p<0.03). Its effect was similar to those of the beta-glucan samples. Oatwell and beta- 
glucan samples promoted the highest mean propionate production at 24 h. 
Xylooligosaccharide resulted in a significant increase in the genus Bifidobacterium after 
24 h of fermentation (0 h: 0.67 OTUs; 24 h: 5.22 OTUs; p = 0.038). Inulin and the dried 
chicory root blend increased the beneficial genus Collinsella, consistent with findings in 
clinical studies. All prebiotic dietary fibers studied promoted the formation of beneficial 
markers due to the fermentation of each specific compound. All compounds provided 
different, significant fermentation patterns, and all provided beneficial effects that would 
promote host health in vivo. 
 
Produce can provide a substantial amount of dietary fiber in the consumer diet, along 
with many other nutrients. Arugula (Eruca sativa), mizuna (Brassica rapa var. 
nipponsinca), red giant mustard (Brassica juncea) and spinach (Spinacia oleracea 
‘Tyee’) are fresh produce crops high in nutritive value and provide shortfall and high 
interest nutrients addressed in the 2015 U.S. Dietary Guidelines. The primary objective of 
this project was to evaluate fertility treatments unique to these crops that optimize their 
nutritional capacity. Plants were grown using five different fertility treatments, including 
four organic treatments and one conventional control. The plant treatment combinations 
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were replicated three times and the entire experiment was duplicated. Fertility treatments 
had a high impact on vitamin C (with over a 3-fold difference in treatments in the first 
experiment), nitrate (over 10-fold difference among fertility treatments in some species) 
and potassium concentrations (over 5-fold difference among fertility treatments in some 
species) in analyzed plant tissue. No consistent differences were found for fiber, calcium, 
iron and sodium concentrations in tissue analyzed. This is the first study to analyze the 
impact that different production treatments can have on multiple deficient nutrients and 
compounds addressed by the U.S. Dietary Guidelines for high-impact, highly-consumed 
produce crops. 
 
Based on in vitro assays, partially hydrolyzed guar gum, wheat dextrin, and 
xylooligosaccharides stimulate the growth of Lactobacilli and Bifidobacteria, the two 
most beneficial genera of bacteria in the gastrointestinal tract. All dietary fibers analyzed 
resulted in significant amounts of short chain fatty acids being produced from their 
fermentation, which was found in all three in vitro studies. Although they are all 
fermentable by fecal bacteria, within healthy donors there can be over a 2-fold total 
difference in acetate, propionate and butyrate production within 24 h of fermentation for 
these dietary fibers. For consumers who prefer to consume dietary fiber in whole foods 
instead of supplements or fortified products, red giant mustard and mizuna both offer 
between 2-4g fiber/serving, which is a “good source of dietary fiber” for the consumer. 
This includes both organic and conventionally grown red giant mustard and mizuna. 
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Like any other dietary component, moderation and variety is still the most important 
factor to consider. Different dietary fibers all support different functions and roles in the 
body, and may all be fermented differently depending on the consumer. Whole foods, 
fortified foods and supplements may all play a critical role in developing a healthy gut 
microbiome, and may all be needed for consumers to meet their recommended daily 
intake.  
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CHAPTER ONE 
Literature Review – Health Benefits of Fiber, Prebiotics and Probiotics: A Review of 
Intestinal Health and Related Health Claims 
 
The original version of this article can be found at Quality Assurance and Safety of Crops 
& Foods 8.4(2016):539-554. The reprint of this article has been used with permission 
from the publisher, as published in agreed format.  
 
Executive Summary 
Gastrointestinal health in regard to the gut microbiome is a rapidly emerging field and 
has many key components driving its emergence. Fiber, prebiotics and probiotics are all 
dietary components that can play a critical role in maintaining a healthy gut microflora. 
Fiber has long been appreciated for its influential role in cardiovascular disease, glycemic 
control and weight management through various physiological mechanisms. Prebiotics 
have been shown to play an influential role in irritable bowel symptoms/disease, colon 
cancer, cardiovascular disease and overall digestive health. Together, various types of 
fibers and prebiotics have been targeted and synthesized to influence the gut microbiome, 
specifically Lactobacillus and Bifidobacterium populations. Lactobacillus spp. and 
Bifidobacterium spp. are common markers for gut health because they have been shown 
to down-regulate inflammation in the gastrointestinal tract, alleviate IBS symptoms, 
stimulate immune functions, aid in mineral absorption and produce little, if any, gas or 
known carcinogenic substances. Probiotics have also been shown to display many of 
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these pro-health components, and include many species of bacteria outside of the 
commonly utilized Lactobacillus and Bifidobacterium populations. How these dietary 
components are defined in the scientific and political arenas will play a critical role in the 
success of the gut health field moving forward. Key changes in administrative definitions 
and requirements of these dietary components will influence consumption, awareness and 
understanding of these key influential components. The purpose of this review is to 
provide current accepted definitions for fiber, prebiotics and probiotics, as well as 
introduce key scientific studies describing the health benefits of these components, as 
well as current health claims.  
 
Introduction 
The gut health field is one of the fastest emerging scientific fields in the public health 
community. Rapid innovation in the biotechnology field has allowed for novel insights 
into the gut microbiome and an understanding of the challenges that are associated with 
analyzing this complex ecosystem.1 The gut microbiome plays a critical role in 
maintaining a healthy lifestyle, driving the necessity to thoroughly understand the dietary 
components that play an influential role in the development of the host’s microflora 
throughout all stages of life,2 and all critical pathways influenced in the body.3 
 
As science emerges quickly on the influence of dietary components on microflora 
development, there is an increasing demand to accurately define the regulated definitions 
for fiber, prebiotics and probiotics.4–6 Clear definitions in the scientific community, as 
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well as for regulatory bodies, will play an influential role in a clear public understanding 
of these easily misunderstood definitions.7,8 Accurate and expandable definitions will 
allow for clear categorization and development of key dietary components that influence 
not only the gut microflora, but how the public views and understands these critical 
components and concepts.  
 
The health benefits of consuming fiber, prebiotics and probiotics are extensive, and in 
some cases overlapping.6,9 Clear scientific studies have led to the development of 
authorized health claims for many of these dietary constituents under the jurisdiction of 
the largest regulatory bodies. The purpose of this review is to introduce and evaluate the 
definitions currently being used/proposed, the scientific studies and literature behind the 
health benefits of these dietary constituents, health claims that are allowed by regulatory 
bodies, and involve adoption of a definition similar to the one proposed by the Institute of 
Medicine (IOM, 2002) (i.e., total fiber [IOM, 2005]). 
 
Fiber Definition 
Fiber definitions in the US have been a highly debated topic over the past 30 years. 
Current changes for the 2015 U.S. Dietary Guidelines, according to the FDA’s new 
proposal, is looking to adapt a similar definition as the 2002 Institute of Medicine (IOM) 
definition of total fiber (IOM, 2005). The Food and Nutrition Board’s Dietary Reference 
Intake (DRI) Standing Committee put forth The Panel on the Definition of Dietary Fiber 
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(Dietary Fiber Panel) in the FDA’s proposed revision to the Nutrition and Supplemental 
Facts Label in March 2013.10 According to The Panel, the definition would include:  
 
1. Non-digestible soluble and insoluble carbohydrates (with 3 or more monomeric units) 
and lignin that are intrinsic and intact in plants. 
2. Isolated and synthetic non-digestible carbohydrates (with 3 or more monomeric units) 
that the FDA has granted to be included in the definition of dietary fiber, in response to a 
petition submitted to the FDA demonstrating that such carbohydrates have a 
physiological effect(s) that is beneficial to human health.  
3. Isolated and synthetic non-digestible carbohydrates (with 3 or more monomeric units) 
that are the subject of an authorized health claim. 
 
According to the FDA’s current regulations and guidance, there are only two isolated 
non-digestible carbohydrates meeting this definition: beta-glucan and barley beta-fiber. 
Although no guidance has been given for analytical methods or documentation required 
to display ‘physiological effect(s) beneficial to human health’, there is speculation that 
the FDA will provide an inclusive list categorizing these components. Labeled fiber 
would then be quantified by the amount determined by the appropriate AOAC method, 
minus the amount of fiber not determined to have a ‘physiological effect(s) beneficial to 
human health’. Currently, the FDA is proposing that manufacturers keep written records 
of all fiber that is contained in food products. The Daily Reference Value (DRV) that is 
used on the Nutrition Facts Panel is also proposed to increase from the current 25 g to 28 
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g. The proposed increase will be affected both by fiber content and definition, potentially 
affecting health claims already in place for various fibers currently in market. This 
proposed change and definition was also introduced in the Scientific Advisory Report of 
the 2015 Dietary Guidelines Committee.11    
 
The U.S. has shifted from the past definition of dietary fiber that was classified with basic 
ethanol dissolution assays, to the current international trend of basing this definition and 
classification to include many new synthetic fibers, largely taking into consideration their 
beneficial impact to the health of the consumer. No new approved analytical methods 
have been unanimously agreed upon, but many definitions for fiber outside the U.S. have 
adapted to these new trends. Proposed protocols to determine whether or not fibers 
display ‘physiological effect(s) beneficial to human health’ will need to be addressed.  
 
In 2009, The World Health Organization (WHO), the United Nations Food and 
Agriculture Organization (FAO) and the Codex Alimentarius Commission (CODEX)12 
have recently stated: “Dietary fiber denotes carbohydrate polymers with 10 or more 
monomeric units that are not hydrolyzed by the endogenous enzymes found in the small 
intestine of humans, belonging to the categories below.” 
 
1. Edible carbohydrate polymers naturally occurring in the consumed food. 
2. Carbohydrate polymers that have been obtained from food raw material by physical, 
enzymatic or chemical means and which have been shown to have physiological benefit 
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to health, as demonstrated by generally accepted scientific evidence to competent 
authorities.  
3. Synthetic carbohydrate polymers that have been shown to have a physiological benefit 
to health, as demonstrated by generally accepted scientific evidence to competent 
authorities. 
 
Noting, this also includes lignin and others compounds quantified by AOAC 991.43 and 
that the decision to include carbohydrates with 3-9 monomeric units should be left to the 
discretion of national authorities.  
 
Currently, the European Food Safety Authority (EFSA) has accepted the most recent 
CODEX method along with Health Canada and Food Standards Australia and New 
Zealand (FSANZ). All three regulatory bodies also include the footnote to include 
substances with 3-9 monomeric units, and accept AOAC 2009.01 as the method to 
correctly measure total dietary fiber with the CODEX definition. AOAC 2011.09 can also 
be used to measure CODEX total dietary fiber.  
 
As the concept of dietary fiber merges with the notion of ‘physiological effect(s) 
beneficial to human health’, we must take into consideration how this will influence 
future definitions and distinctions of prebiotics and what they mean to consumer health 
and the food industry, both scientifically and politically. Definitions also need to be 
defined as flexible enough to take into consideration the improvements in the 
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biotechnology and microbiology fields, so technological advances do not outpace current 
regulatory changes.  
 
Prebiotic Definition 
The first active and published definition of the word “prebiotic” was defined in 1995 as, 
‘nondigestible food ingredients that beneficially affect the host by selectively stimulating 
the growth and/or activity of one or a limited number of bacteria in the colon, thus 
improving host health’,13 and eight years later changed to include, ‘a selectively 
fermented ingredient that allows specific changes, both in the composition and/or activity 
in the gastrointestinal microbiota that confers benefits’.14 In 2010 the International 
Scientific Association for Prebiotics and Probiotics (ISAPP) widened that definition to 
include focus on the functionality of prebiotics, ‘a selectively fermented ingredient that 
results in specific changes in the composition and/or activity of the gastrointestinal 
microbiota, thus conferring benefit(s) upon host health’.15 
 
Important to note is that all prebiotics can be classified as fiber, although not all fibers are 
considered prebiotic.16 Characteristics of functional prebiotics include: the ability to resist 
the low pH of the stomach, resist hydrolysis by mammalian enzymes, resist absorption in 
the upper gastrointestinal tract, the ability to be fermented by intestinal microbiota and 
selectively stimulate the growth and/or activity of intestinal bacteria associated with host 
health and overall well-being.13,14 It is generally accepted that beneficial bacteria includes 
bifidobacteria and also lactobacilli. Increased growth of lactobacilli due to stimulation of 
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prebiotics is often less prevalent because of lower overall concentrations compared to 
bifidobacteria in the gastrointestinal tract.  
 
The need to develop universal methods for specific, quantifiable results in clinical studies 
will result if fiber regulations need to show ‘physiological effect beneficial to human 
health’ in the U.S. The general notion of beneficial stimulation of Bifidobacteria and 
Lactobacillus, as typically used to determine beneficial prebiotic capacity of molecules, 
will need quantifiable target ranges for stimulated populations of bacteria that are 
representative for universal populations in the U.S.  
 
Probiotic Definition 
The FAO/WHO defines probiotics as, “live mircroorganims that, when administered in 
adequate amounts, confer a health benefit to the host” which is a generally accepted 
definition.5,17 In the U.S., the FDA may define a probiotic as a drug, biological product, 
dietary supplement, food or food ingredient.18 Both the FDA and EFSA have a similar 
stance, and have generally accepted the FAO/WHO definition of probiotics. Unlike 
Canada, the FDA and EFSA have yet to allow any health claim associated with probiotic 
products.  
 
Health Benefits of Fiber 
Cardiovascular disease 
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Dietary fiber, especially soluble fiber, has been consistently shown to protect against 
CVD, but the exact functional components and mechanisms remain slightly unclear.19 
Soluble fiber has been shown to decrease serum cholesterol, primarily by decreasing low-
density liproprotein cholesterol.20 Bazzano et al21 conducted an epidemiologic follow-up 
assessment study with an average time of 19 years of follow up, including 1843 cases of 
CHD and 3762 cases of CVD and found that a higher intake of soluble fiber (5.9 g/d 
compared to 0.9 g/d) reduces risk of CHD.  Bazzano et al21 conducted a pooled analysis 
of ten prospective cohort studies in the U.S. and Europe and found that the consumption 
of dietary fiber from cereals and fruits is inversely associated with risk of CHD. Viscosity 
influences the protective effects against CVD and CHD, but other mechanisms include 
decreases in C-reactive protein22–25 and decreases in blood pressure26–28 due to higher 
consumption of dietary fiber. 
 
In the U.S. the FDA states that there is sufficient evidence for beta-glucans in oats and 
barley, and also psyllium husk, to authorize health claims to reduce the risk of heart 
disease for foods containing 0.75-1.7 g of soluble fiber.29,30 EFSA has approved function 
health claims for beta-glucans from oat, oat bran, barley and barley bran for food 
products that contain at least 1 g of beta-glucans from these sources (pure or mixed), 
while informing the consumer that they must consume 3 g daily to contribute to the 
maintenance of normal blood cholesterol levels.31  
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Glycemic Response and Diabetes Control 
The relationship between fiber consumption and the development and control of type II 
diabetes includes many working theories and mechanisms. Mechanisms include increases 
in satiety cues that may lead to decreased caloric intake, thus, lesser weight gain, the 
ability of soluble, viscous fibers to attenuate glucose absorption rates, increase absorption 
and availability of nutrients and stimulate beneficial bacteria in the colon that may play 
an unknown role in the onset of type II diabetes. 
 
Hopping et al32 conducted a large-scale prospective multiethnic cohort study with 75,512 
participants over a span of 14 years. Total dietary fiber intake was inversely associated 
with overall diabetes risk for all populations analyzed (Men HR: 0.75; 95% CI: 0.67, 
0.84; P-trend <0.001 and Women HR: 0.95; 95% CI: 0.85, 1.06; P-trend = 0.05), and 
people who consumed greater than 15 g of fiber a day had significantly lower diabetes 
risk (p<0.05). Meyer et al33 conducted a prospective cohort of 35,988 women for 6 years. 
Intakes of 17 g/d of insoluble fiber and 8 g/d of cereal fiber led to a decreased risk of the 
onset of type II diabetes (p=0.0012 and p=0.0001, respectively), while there was no 
positive association between soluble fiber intake. Schulze et al34 conducted a similar 
cohort analysis of 91,249 young women for 8 years and found that low cereal fiber intake 
(<4.4 g/d) resulted in higher risk of developing type II diabetes.  
 
Short-term intervention studies have displayed mixed results depending on dosage, fiber 
type and population analyzed. A recent meta-analysis of 34 oat and barley fiber studies 
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concluded that 3 g of beta-glucans from intact foods and 4 g of beta-glucans from 
processed foods is enough to significantly lower post-prandial glucose concentrations 
with 4 g of beta-glucans resulting in a decreased glycemic response of 27  3 mmol  
min/L.35 Analysis of many short-term studies found no correlations between fiber intake 
and post-prandial glucose concentrations.36 Mechanisms for fiber intake and type II 
diabetes prevention remain largely unclear with mixed results short-term, while long-
term studies have found many positive associations between fiber intake and decreased 
risk of onset of type II diabetes. 
 
Weight Maintenance  
Fiber intake and obesity prevention has been extensively reviewed.37 It is generally 
recognized that dietary fiber intake supports weight loss and maintenance, although exact 
mechanisms remain unclear. Supported hypotheses include promotions in satiety cues,38 
alterations in absorption of select macronutrients,39 altering patterns and concentrations 
of gut hormones40–46 and overall decreases in caloric intake. Heaton et al47 first 
introduced three primary hypothesized mechanisms of decreasing absorption efficiency 
in the small intestine, fiber displacing higher caloric nutrients in foods and promotion of 
saliva and gastric juice secretion due to increased mastication. Many mechanisms remain 
unclear and inconsistent at best. Cross-sectional observational studies have shown 
consistently an inverse relationship between fiber intake and BMI and body fat across 
many ages and populations.48–51 Several observational studies have shown that obese 
adults have significantly lower dietary fiber intake.52,53 
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US Fiber Health Claims   
Currently, the FDA has allowed approved health claims for soluble fibers in foods from 
barley, psyllium and oats.19 There are only twelve allowed health claims allowed on 
labels in the U.S., with three of them (only two discussed) dedicated to dietary fiber 
(Table 1-4). Additional labeling describing quantities of fiber (nutrient content claims) on 
packages are allowed.54 To claim a product is “High” in dietary fiber, the product must 
contain 20% or more of the daily value (DV) per RACC, while a “Good Source” claim 
requires 10-20%.  
 
European Fiber Health Claims  
European health claims are covered by the Nutrition and Health Claims Regulation 
(NHCR) which includes: social media, print media, websites, presentations and product 
labels. The European Commission (EC) has overall authorization. Allowable health 
claims are categorized as: General Function (Article 13(1)), Emerging Science (Article 
13(5)), Disease Risk Reduction (Article 14(1)a), Children’s Health (Article 14(1)b). 
Health claims are authorized for wheat, barley, oat, rye and sugar beet fiber (Table 1-5). 
 
Health Benefits of Prebiotics 
Inflammatory Bowel Disease 
A recent randomized, double-blind, crossover study with twenty subjects with an ileal 
pouch-anal anastomosis receiving 24 g of inulin or a placebo for three weeks was 
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conducted. After three weeks, subjects exhibited increased butyrate concentrations (11.7 
mmol/g in placebo and 18.9 mmol/g in inulin group), decreased Bacteroides fragilis 
(7.68 CFU/g in placebo and 6.77 CFU/g in inulin group) and lowered concentrations of 
bile acids in the feces (1.66 mol/g in placebo and 1.42 mol/g in treatment group), 
while reducing inflammation of the mucosa of the ileal reservoir under histological and 
endoscopical analysis.55 A randomized, double-blind, placebo-controlled trial with 103 
patients with active Crohn’s disease fed a 15 g/d supplement of FOS or placebo for four 
weeks was conducted, and found no significant differences in Bifidobacteria or 
Faecalibacterium prausnitzii, concluding no significant clinical benefit to 
supplementation with 15 g/d of FOS.56 Limited studies have shown consistent findings on 
alleviation of IBD symptoms with prebiotics. Many successful studies have utilized 
similar paired prebiotic and probiotic treatments with consistent success in lessening 
symptoms of IBD and related health issues.57  
 
Colon Cancer 
Inulin, oligofructose, lactulose and resistant starch are all prebiotics that have been 
analyzed for their role in colorectal cancer risk.58 Roncucci et al59 researched the effect of 
supplementing 209 adults who previously had polyps removed consuming 20g/d of 
lactulose for three years. Significant reduction in adenoma recurrence was found at the 
end of the study, of the 61 subjects analyzed only 9 had recurrence while 61 saw no 
recurrence post-treatment, although no placebo or comparison group was included in this 
study. Langlands et al60 conducted a 2-week study with 29 healthy adults, divided into an 
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experimental and control group. Oligofructose (7.5g) and 7.5 g of inulin were consumed 
daily in this study, with the control group not consuming a supplement. Bifidobacteria 
increased from 6.6 to 7.3 log10 CFUs (p<0.001) and lactobacilli increased from 3.0 to 3.7 
log10 CFUs (p=0.02). MCM2 and Ki67 markers were measured for changes in cell 
proliferation, although no significant differences were found. Limberg et al61 conducted a 
randomized, phase II chemoprevention trial with 85 subjects over 40 with previously 
resected colon cancer or multiple/advanced adenomas. No changes were seen for any 
measurements (aberrant crypt foci, Ki67 and caspase -3) for subjects consuming 12 g/d of 
oligofructose-enriched inulin. Many studies have researched the potential influence of 
resistant starches on colorectal cancer. Worthley et al62 conducted a randomized, double-
blind, placebo-controlled 4-week crossover trial. No significant differences in epithelial 
proliferation or crypt height were noted for the subjects consuming 25 g/d of RS2. 
Wacker et al63 found no effect on cell proliferation determined by bromodeoxyuridine 
labeling for the 12 volunteers consuming 50-60 g/d of RS in starchy foods during their 
two 4-week periods of a supplemented, controlled diet. Many studies with varying 
amounts of RS supplements have all found similar results.64–67 Prebiotics have displayed 
many potential protective effects against colorectal cancer in various animal models, but 
there has been limited evidence in human studies.68 The current hypotheses include 
effects of SCFAs, stimulated immunity of the host and many anticarcinogenic 
pathwways.  
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Cardiovascular Disease  
Causey et al69 conducted a randomized, double-blind crossover study with twelve men 
with hypercholesterolemia divided into two controlled diets. One included a pint of ice 
cream with 20 g of inulin, and one a pint of ice cream with sucrose. Daily intake of 20 g 
of inulin significantly reduced serum triglycerides by 40 mg/dL (p=0.05), increased 
butyrate concentrations (0.91mmol/L in control phase and 1.96 mmol/L in inulin phase) 
and did not significantly alter any change in transit time. Brighenti et al70 researched the 
effects of inulin in ready-to-eat cereals in twelve healthy male volunteers. Volunteers 
consumed 50 g of rice-based cereal with 18% inulin daily for three periods throughout 
four weeks. They found no changes in fecal SCFAs or pH, but found plasma total 
cholesterol decreased significantly (p<0.05) and triacylglycerol decreased (p<0.05) at the 
end of each test period while bifidobacteria concentration increased (p<0.05). Gluconic 
acid, germinated barley, oligodextrans, lactose, glutamine, hemicellulose rich substrates 
and many types of resistant starches are all prebiotic compounds that have been targeted 
for their cholesterol-lowering effects. Although identified, no specific daily dosage has 
been established for these effects, resulting in conflicting study results.71  
 
Prebiotic Regulatory Status 
Authoritative governing branches have been strained to keep up with the rapidly growing 
field of prebiotics. In the U.S., commonly consumed prebiotics include inulin, fructo-
oligosaccharides (FOS) and galacto-oligosaccharides (GOS) primarily due to their tenure 
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in the U.S. are being regarded as safe and effective,72 thus increasing their consumption. 
All foods and ingredients are regulated under the Food Drug and Cosmetic Act, which 
clearly states that the safety of introduced ingredients and foods is the responsibility of 
the company manufacturing the product. For items that are not Generally Recognized As 
Safe (GRAS), they are required to obtain FDA approval before products can be sold 
commercially. Although approval may be obtained for ingredients that act as what is 
generally defined as “prebiotic”, neither the FDA in the U.S. nor EFSA in the European 
Union have established a legal definition for a prebiotic.73,74 Cited above, EFSA currently 
uses the FAO definition of a prebiotic, indicating the need to display a health benefit.73,75 
Challenges exist for regulatory bodies in that the scientific community does not have a 
universally agreed upon definition for the term prebiotic, a key first step in addressing 
these regulatory issues.4 Challenges will also be faced as fibers are required to display 
“physiological effects beneficial to human health”, as this may blend into the current 
opinions and definitions at stake.  
 
Health Benefits of Probiotics 
Currently, there are no health claims associated with probiotic products in the U.S., or 
recommendations for probiotic consumption. In Europe, EFSA has taken a similar 
approach. Canada has accepted and regulated claims and health benefits for identified 
probiotics (Table 1-1), and have identified probiotic species known to promote health 
benefits in the gastrointestinal tract and body.76–78 Health impacts of probiotics have been 
well-documented (Table 1-2 and 1-3) and include the ability to reduce severity of 
   17
symptoms of IBS,79–81 preventing and reducing various types of diarrhea,82–84 improving 
overall lipid profiles85 and many more.86 Commonly used microorganisms as probiotics 
usually belong to the Lactobacillus and Bifidobacterium genera, but many others are 
commonly used, including: Streptococcus thermophilis, Streptococcus diacetylactis 
Streptococcus intermedius, Lactococcus lactis, Leuconstoc mesenteroides, 
Saccharomyces bourlardii, Saccharomyces cerevisae and Escherichia coli strain Nissle. 
 
Fiber, Prebiotic and Probiotic Consumption 
Fiber consumption in the U.S and other countries is typically half of what is 
recommended by governing regulating bodies. In the U.S., current intake of fiber is 
typically around 17 g/d, while recommendations are 25 g/d and 38 g/d for women and 
men, respectively. Similar consumption patterns are seen in Europe and other 
industrialized countries.87 Fortified foods have evolved to help bridge the gap between 
consumption and recommendations, but further progress needs to be made. Changes in 
definitions and analytical methods have also been suggested as a means to address the 
‘fiber gap’ in many countries.88 
 
Inulin is a prebiotic that occurs naturally in leeks, asparagus, onions, wheat, garlic, 
chicory, oats, soybeans and Jerusalem artichokes. Estimated consumption in U.S and 
European diets is several grams a day for naturally occurring prebiotics (inulin and 
FOS).89,90 At this dosage, it may be improbable that naturally-occurring prebiotics may 
have any beneficial effect. Without universal definitions of prebiotics and inclusive lists 
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of ingredients included, epidemiological tracking of prebiotic consumption patterns will 
be difficult to obtain. 
 
 Probiotic consumption is hard to quantitate due to its diverse origin across many food 
categories. Probiotic milk products, a common subset of probiotic products, are very 
widely consumed.91 In Finland, sour milk is reportedly consumed by over 90% of 
respondents.92 Japan and Belgium have much lower consumption rates, with less than 5% 
of respondents consuming fermented dairy products.93,94  
 
The Evolution of Intestinal Health 
Microbiome Composition 
Many ecosystems co-exist throughout the human gastrointestinal tract. Outside of the 
distal intestine, diverse ecosystems exist on the skin, parts of the oral cavity and also the 
urogenital tract. The oral cavity microbiota contains over 500 diverse bacterial species.95 
Depending on exposure and quality of hygiene, evidence suggests that these bacteria are 
responsible for a wide array of systemic diseases.96 The stomach also contains between 
102 to 103 CFU/mL of stomach contents, primarily due to the low pH of the stomach.97 
The distal intestine is the primary home of the human gut microbiome, a diverse and 
complex ecosystem containing between 1010 to 1012 CFU/g of cells, belonging to 
hundreds of species of bacteria.98–101 It is estimated that up to 30 g of bacteria are 
produced for every 100 g of carbohydrate fermented in the distal intestine.6 By volume, 
bacteria compose 30% of the human colon.102 There are many abundant genera of 
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bacteria in the distal intestine, including: bacteroides, eubacteria, fusobacteria, 
bifidobacteria, peptostreptococci, clostridia, lactobacilli and streptococci.103 The gut 
microflora serves as the primary, interchangeable interface between the diet and the 
host’s health, and has recently been associated with many diseases and conditions.104 
Advances in clinical studies and biotechnology are leading the way to successful 
modulation of the gut microflora, improving knowledge of many disease states and 
pioneering diets and functional foods that will continue to aid in health promotion. 
 
Influences on the Gut Microbiome and Intestinal Health  
Establishment of a healthy gut microbiota starts immediately at birth, although this 
progression is highly debated, partly due to the complexity of defining what a “healthy 
microbiome” entails. It is well-established that fiber and other non-digested food contents 
play a large role in the influence and development of the host’s microflora.105 Other 
influential factors include: age, stress, infection, geography and many other 
environmental componenets.106–110 Independent of the geography of populations, specific 
species of Bifidobacteria have been shown to decrease with increasing age.110 Stress has 
also been shown to influence certain bacteria over extended periods of time.111 
Differences in delivery between either caesarean section or the vaginal canal play a 
critical role in the early development of the microbiota,112–114 and leads to both changes 
in bacterial composition and also the timing of advanced colonization.114–117 At ages 1-3, 
most individuals have colonization most similar to adult populations.113,118 Studies have 
shown that breast-fed infants have a microflora dominated by bifidobacteria populations, 
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114,119,120 while other studies have shown bifidobacteria to be much less prevalent.121,122 
Extreme biodiversity exists among individuals, making identifying a healthy microbiome 
difficult. As dietary constituents continue to aim at improving gut health, continued 
research is needed to examine the full effects of exogenous factors on host development. 
 
Influential Roles of Lactobacilli and Bifidobacteria 
Because of the many health-promoting properties of these genera of bacteria they are 
commonly used markers of microflora health, and common targets for dietary 
stimulation.  Lactobacilli have been shown to down-regulate mucosal inflammation in the 
gastrointestinal tract.123 Lactobacilli play a role in helping digest lactose for lactose-
intolerant individuals, alleviate constipation, improve IBS symptoms and potentially help 
prevent traveler’s diarrhea.124 Bifidobacteria and lactobacilli also inhibit the growth of 
harmful bacteria, stimulate immune functions throughout the body, aid in mineral 
absorption and help in the synthesis of vitamins.125 Bifidobacteria reside naturally in the 
gastrointestinal tract of healthy human adults and have a strong affinity to ferment select 
oligosaccharides, making them a common marker for prebiotic capacity. Bifidobacteria 
are a unique genus of bacteria in that no gas is formed as an end product of 
metabolism.126 Similar to the Lactobacillus genera, these bacteria are saccharolytic, an 
often used marker for beneficial bacteria.102 Bifidobacteria also don’t produce any known 
carcinogenic substances in vivo. Bifidobacteria concentrations have been negatively 
associated with obesity and weight gain.127–130 Specific species might play a critical role 
in this association, as not all species of bifidobacteria may have identical influence.131 
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Decreased levels of bifidobacteria and lactobacilli have been positively associated with 
the development of allergy diseases in the first five years of life.132,133 Decreases in 
bifidobacteria, along with decreases in bacterial diversity, have been associated with 
higher inflammation and IBS.134,135 The mechanisms behind disease states and 
lactobacilli and bifidobacteria are unclear, but sufficient studies show these bacteria are 
highly associated with improved health. 
 
Conclusions 
Fiber, prebiotics and probiotics have all been shown to play an influential part in 
developing and maintaining a healthy microbiota throughout all stages of life. As gut 
microbiome research continues to advance our understanding of the significance and 
importance of this diverse ecosystem, critical importance should be placed on public 
awareness of this topic. Categorization and definitions of these critical dietary 
components will be influential in advancing the understanding of the gut microbiome. 
Health claims should continue to place importance on the roles that these dietary 
components can play in maintaining a healthy lifestyle and their importance in various 
diseases and conditions. As science advances our understanding of the critical 
components that influence the gut microbiome through the diet, regulation of these 
dietary components will play a critical role in the perception and consumption of fiber, 
prebiotics and probiotics.  
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Table 1-1. Lactobacillus and Bifidobacterium microorganisms most commonly used as 
probiotic supplements worldwide.  
Bifidobacterium Lactobacillus  
B. adolescentis L. acidophilus 
B. animalis L. casei 
B. animalis subsp. animalis L. crispatus 
B. animalis supsp. lactis L. fermentum 
B. bifidum L. gasseri 
B. breve L. johnsonii 
B. infantis L. plantarum 
B. lactis L. reuteri 
B. longum L. rhamnosus 
B. thermophilum L. salivarius 
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Table 1-2. Bacterial species with accepted non-strain-specific probiotic claims in foods in 
Canada.77,78,136–138  
Bacterial Species Eligible Claims Conditions Substantiation 
Requirements 
Bifidobacterium adolescentis  
Bifidobacterium animalis subsp. 
animalis 
Bifidobacterium animalis subsp. 
lactis 
Bifidobacterium bifidum 
Bifidobacterium breve 
Bifidobacterium infantis 
Bifidobacterium longum 
“Probiotic that 
naturally forms part 
of the gut flora” 
 
“Provides live 
microorganisms that 
naturally form part of 
the gut 
flora/contribute to 
healthy gut flora” 
 
“Probiotic that 
contributes to healthy 
gut flora” 
At least 1.0 x 109 
colony forming 
units of one or 
more eligible 
microorganisms 
per serving 
 
Must declare 
genus, species 
and strain in 
labeling 
 
Recommended to 
included ATCC 
assigned number 
None 
Lactobacillus acidophilus 
Lactobacillus casei 
Lactobacillus fermentum 
Lactobacillus gasseri 
Lactobacillus johnsonii 
Lactobacillus paracasei 
Lactobacillus plantarum 
Lactobacillus rhamnosus 
Lactobacillus salivarius 
None 
 
 
Bacteria not listed above 
 
Claims need to be 
validated and 
wording of claim 
specific 
Need strain-
specific human 
efficacy evidence 
 
Require genus, 
species and strain 
in labeling 
Yes. Strain- 
specific human 
efficacy 
evidence 
required. 
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Table 1-3. Probiotic health claim criteria for natural health products.  
Species Eligible 
Claims/Purposes 
Conditions 
Bifidobacteria adolescentis  
Bifidobacteria animalis subsp. animalis 
Bifidobacteria animalis subsp. lactis 
Bifidobacteria bifidum 
Bifidobacteria breve 
Bifidobacteria infantis 
Bifidobacteria longum 
 
 
“Probiotic that 
forms/contributes to a 
natural healthy gut 
flora” 
 
“Probiotic to benefit 
health and/or to confer a 
health benefit” 
 
“Provides live 
microorganisms that 
form part of a natural 
healthy gut flora/that 
contribute to a natural 
healthy gut flora/benefit 
health/confer a health 
benefit” 
 
 
 
1.0 x 107 to 1.0 x 1011 
colony forming units 
of one or more 
eligible 
microorganisms per 
day 
 
 
Lactobacillus acidophilus 
Lactobacillus casei 
Lactobacillus fermentum 
Lactobacillus gasseri 
Lactobacillus johnsonii 
Lactobacillus paracasei 
Lactobacillus plantarum 
Lactobacillus rhamnosus 
Lactobacillus salivarius 
 
 
 
 
 
Lactobacillus Rhamnosus GG 
 
“Helps to manage acute 
infectious diarrhea” 
 
 
 
6.0 x 109 to 1.2 x 1010 
colony forming units/day 
 
 
 
“Helps to 
manage/reduce 
antibiotic-associated 
diarrhea” 
 
1.0 x 1010 to 2.0 x 1010 
colony forming units/day 
 
 
Lactobacillus johnsonii La1/Lj1/NCC533 “An adjunct to 
physician-supervised 
antibiotic therapy in 
patients with 
Helicobacter pylori 
infections 
1.25 x 108 to 3.6 x 109 
colony forming units/day 
Saccharomyces boulardii 
Saccharomyces cerevisiae 
“Helps to reduce the risk 
of antibiotic-associated 
diarrhea” 
1.0 x 1010 to 3.0 x 1010 
colony forming units/day 
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Table 1-4. FDA authorized health claims regarding dietary fiber and disease.  
Target of Claim Product 
Requirements 
Required Terms Model Statement 
 
 
Soluble Fiber and 
Risk of Coronary 
Heart Disease 
1. Low Saturated Fat 
2. Low Cholesterol 
3. Low Fat, and 
  
Must Contain 
Whole Oat/Barley 
Foods, or 
 
Oatrim that contains 
0.75 g Beta-
glucan/RACC, or 
 
Psyllium husk that 
contains 1.7 g of 
soluble fiber/RACC1 
 
“Heart Disease” or 
“Coronary Heart 
Disease” 
 
“Saturated Fat” 
 
“Cholesterol” 
 
Specify type of 
soluble fiber 
 
Specify amount of 
soluble fiber/serving 
 
“Soluble fiber from 
foods such as 
[product], as part of 
a diet low in 
saturated fat and 
cholesterol, may 
reduce the risk of 
heart disease. A 
serving of [product] 
supplies [g] of the 
soluble fiber 
necessary per day to 
have this effect.” 
 
 
Beta-Glucan 
Soluble Fiber (Oat 
and Barley 
Sources) 
1. Oat bran, or 
2. Rolled oats, or 
3. Whole oat flour, 
or 
4. Oatrim, or 
5. Whole grain 
barley and dry 
milled barley, or 
6. Barley beta fiber, 
or 
7. Soluble fiber from 
psyllium husk with 
purity of <95% 
 
The amount of 
soluble fiber/RACC 
must be declared on 
nutrition label.  
 
“Heart Disease” or 
“Coronary Heart 
Disease” 
 
“Saturated Fat” 
 
“Cholesterol” 
 
Specify type of 
soluble fiber 
 
Specify amount of 
soluble fiber/serving 
 
“Soluble fiber from 
foods such as 
[product], as part of 
a diet low in 
saturated fat and 
cholesterol, may 
reduce the risk of 
heart disease. A 
serving of [product] 
supplies [g] of the 
soluble fiber 
necessary per day to 
have this effect.” 
1 Foods bearing a psyllium seed husk health claim must also bear a label statement 
concerning the need to consume them with adequate amounts of fluids. 
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Table 1-5. Current EFSA requirements for health claims in the European Union.  
Claim Type Nutrient Claim Summary Health Relationship 
Article 13(1) 139  
Arabinoxylan from 
wheat endosperm 
“Consumption of 
arabinoxylan as part 
of a meal contributes 
to a reduction of the 
blood glucose rise 
after that meal” 
 
Reduction of post-
prandial glycaemic 
responses 
Article 13(5) 
(EUR-Lex, 2014)   
 
Sugar beet fibre 
“Sugar beet fibre 
and increasing faecal 
bulk” 
 
Increasing faecal 
bulk 
Article 13(1) 139  
Wheat bran fibre 
“Wheat bran fibre 
contributes to an 
increase in faecal 
bulk” 
 
Increase in faecal 
bulk 
Article 13(1) 139   
Wheat bran fibre 
“Wheat bran fibre 
contributes to an 
acceleration of 
intestinal transit” 
 
Reduction in 
intestinal transit 
time 
Article 13(1) 139   
Barley grain fibre 
“Barley grain fibre 
contributes to an 
increase in fecal 
bulk” 
 
Increase in faecal 
bulk 
Article 13(1) 139  
Oat grain fibre 
“Oat grain fibre 
contributes to an 
increase in faecal 
bulk” 
 
Increase in faecal 
bulk 
Article 13(1) 139  
Rye fibre 
“Rye contributes to 
normal bowel 
function” 
Changes in bowel 
function 
 
Article 13(5) 
(EFSA, 2015) 
 
Chicory Root Inulin 
“Chicory root inulin 
contributes to 
maintenance of 
normal defecation” 
 
Increasing stool 
frequency 
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CHAPTER TWO 
Prebiotic Effects and Fermentation Kinetics of Wheat Dextrin and Partially Hydrolyzed 
Guar Gum In An In Vitro Batch Fermentation System 
 
The original version of this article can be found at Foods 4.3(2016):349-358. The reprint 
of this article has been used with permission from the publisher, as published in agreed 
format.  
 
Executive Summary 
Scientific research demonstrates that two indigenous gut bacteria, Lactobacillus and 
Bifidobacterium can contribute to human health. The primary objective of this in vitro 
study was to quantitatively analyze at the genus level how wheat dextrin (WD) and 
partially hydrolyzed guar gum (PHGG) increased the levels of these two gut bacteria at 
12 h and 24 h, via real time quantitative polymerase chain reaction (qPCR). Secondary 
objectives were changes in fecal pH, short chain fatty acids (SCFAs) and total gas 
volume produced. At 12 h WD was significantly more bifidogenic (9.50 CFU log10/mL) 
than PHGG (9.30 CFU log10/mL) (p=0.052), and also at 24 h WD (9.41 CFU log10/mL) 
compared with PHGG (9.27 CFU log10/mL) (p=0.043). WD produced less total SCFAs at 
both 12 h and 24 h than PHGG, and produced significantly lower amounts of gas at 12 h 
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and 24 h (p<0.001, p<0.001). Both PHGG and WD also promoted growth of Lactobacilli 
when measured at 12 h and 24 h compared with the 0 h analysis, indicating that both 
fibers are lactogenic. These results demonstrate the prebiotic effect of WD and PHGG. 
Based on fermentation kinetics, PHGG is more rapidly fermented than WD, and both 
fibers show prebiotic effects as early as 12 h. 
 
Introduction 
Dietary fiber is generally defined as nondigestible carbohydrates and lignin that are 
intrinsic and intact in plants, with functional fiber showing beneficial physiological 
effects in humans.19 Currently the U.S. recommendations for dietary fiber, expressed as a 
Dietary Reference Intake, are 25 g/d for adult females and 38 g/d for adult males, 
although the typical daily intake for U.S. consumers is approximately 17g/d.140,141 
Generally accepted health benefits associated with regular fiber consumption include 
maintaining a healthy digestive system, increased satiety, decreased  caloric intake, and 
fermentation that results in beneficial changes in the gut microflora.6,37 Daily 
supplementation of beneficial dietary fibers may be an effective way to help consumers 
get the recommended amount of dietary fiber, and its associated health benefits.  
 
Wheat dextrin (WD) and partially hydrolyzed guar gum (PHGG) are dietary fibers 
evaluated in this study. WD is a soluble, fermentable fiber composed of a glucose 
polymer formed by the polymerization and hydrolysis of wheat starch that resists 
digestion in the small intestine due to its glucoside linkages.142 PHGG is a hydrolyzed 
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product of guar gum, composed of mannose and galactose monomers. Clinical studies 
have shown that 45g/d of WD is well tolerated in the gastrointestinal tract.143 WD also 
has been shown to decrease hunger and increase satiety in a randomized, double-blind, 
placebo-controlled study.144–146 PHGG has been shown in randomized, cross-over clinical 
studies to reduce hunger and increase satiety.147,148 
 
Two different soluble fibers were selected in this study to help understand the 
mechanisms of action and subsequent changes in gut microflora through the use of an in 
vitro batch fermentation model. In vitro fermentation methods are a representative model 
of colonic fermentation, and work well to predict substrate availability and ability for 
fermentation in the gut.149 Previous preliminary studies have shown that WD and PHGG 
ferment in the large intestine producing measurable levels of beneficial Bifidobacteria 
and Lactobacillus at 24 h, indicating that both dietary fibers demonstrate a prebiotic 
effect.150  
 
The primary objective of this study was to measure changes in two beneficial genera of 
microbes, Lactobacillus and Bifidobacterium, to better understand the prebiotic effects of 
WD and PHGG and their mechanisms of action. Secondary objectives included 
measurements of common fermentation markers, such as pH, total gas volume and short-
chain fatty acids (SCFA).  
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Materials 
Fibers investigated in this study included wheat dextrin (Benefiber®, Novartis Consumer 
Health Inc., USA) and partially hydrolyzed guar gum (Benefibra™, Novartis Consumer 
Health Spa Origgio, Italy). A substrate blank was employed for all baseline 
measurements in fecal inoculum. Chemical reagents used in this study were provided by 
ThermoFisher Scientific (ThermoFisher Scientific Inc., Waltham, MN), Sigma-Aldrich 
(Sigma-Aldrich, St. Louis, MO) and Oxyrase (Oxyrase Inc., Mansfield, OH).  
 
Methods 
Fecal Collection 
Fecal samples were collected from three healthy volunteers (2 males, 1 female) under 
anaerobic conditions from three individuals (ages 18-28) consuming non-specific 
Western diets, free of antibiotic treatments in the last 6 months, not affected by any GI 
diseases and not consuming any prebiotic or probiotic supplements. Fecal samples were 
anaerobically collected within 1 hour of the start of the batch fermentation and 
homogenized, and combined, immediately upon collection.  
 
Fermentation 
Fiber samples (0.5 g) were hydrated in 40 mL of prepared sterile tricase peptone 
fermentation media in 100 mL serum bottles, capped to avoid contamination, and 
incubated for 12 hours at 4°C. Following incubation, serum bottles were transferred to a 
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circulating water bath at 37°C and allowed to incubate for 2 hours. Post-collection, fecal 
samples were homogenized using a 6:1 ratio of phosphate buffer solution to fecal matter. 
After mixing, obtained fecal slurry was combined with prepared reduction solution (2.52 
g cysteine hydrochloride, 16 mL 1N NaOH, 2.56 g sodium sulfide nonanhydride, 380 mL 
DD H2O) at a 2:15 ratio. 10 mL of the prepared fecal inoculum was added to each of the 
serum bottles, 0.8 mL Oxyrase® added, flushed with CO2, sealed, and then immediately 
placed in the 37°C circulating water bath. Samples were prepared in triplicate and 
analyzed at 0, 4, 8, 12 and 24 hours. Triplicate positive controls (dextrose) and negative 
controls (substrate blank) were also analyzed at the same time points. Upon removal at 
appropriate time point, pH and total gas volume were measured. Then, 1 mL of copper 
sulfate (200 g/L) was added to cease fermentation. Lastly, 2 mL aliquots were frozen at   
-80°C for further analysis. 
 
pH Analysis 
2 mL aliquots were removed from serum bottles immediately following total gas 
measurement and measured with an Orion PerpHect LogR Meter – Model 350 (Orion 
Research, Inc. Boston, MA). 
 
Gas Analysis 
Total gas production (volume) was measured by syringe difference analysis. Gas was 
measured by piercing cap of serum bottle with syringe needle and measuring gas released 
from system. 
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SCFA Analysis 
SCFA extraction methods were adapted and modified from Schneider et al.151  2 mL 
aliquots were removed from the -80°C freezer and placed in 4°C cooler for 12 hours to 
thaw prior to SCFA analysis. Tubes were then gently vortexed for 5 seconds. Then, 1.6 
mL of DI H20, 400µL H2SO4 (50% vol/vol), and 2 mL diethyl ether (premixed with 2-
ethyl butyric acid as internal standard) were all added to tubes and vortexed again for 5 
seconds. Tubes were then placed in an orbital shaker for 45 minutes at 100 RPM. Tubes 
were removed and then centrifuged for 5 minutes at 3000 RPM. Supernatant was 
removed from tube and placed in 10 mL plastic tubes containing CaCl2 to remove any 
residual water. Solution was then filtered using a BD 1 mL syringe (Becton, Dickinson 
and Company Franklin Lakes, NJ) and a Millex 13 mm nylon membrane filter with a 
0.20 µm pore size (Merck Millipore Ltd Tullagreen, Carrigtwohill, Co. Cork, Ireland).   
Extractions were then analyzed using a HP 5890 series gas chromatograph (Helwitt 
Packard, Palo Alto, CA) with a 30 m x 0.250 mm x 0.25 µm polyethylene glycol (PEG) 
column (Agilent Technologies, Santa Clara, CA), with a 110°C oven temperature. 
Samples were injected using an automated HP 7673 GC/SFC injector (Helwitt Packard, 
Palo Alto, CA). Injector and detector temperatures were 220°C and 240°C, respectively. 
Flow rates for air, helium and hydrogen were 26, 28 and 315 mL/min, respectively. All 
samples were analyzed with a 50:1 split ratio. 
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Microbiota Analysis – Quantitative polymerase chain reaction (qPCR) 
Bifidobacterium genus and Lactobacillus genus were quantified by DNA extraction from 
fermented samples, followed by qPCR using specific primers, described in Hernot et al. 
Amplification was performed in a set of triplicate reactions for each bacterial group 
within each sample according to the procedures of Hernot et al.152 For amplification, 10 
µl final volume containing 2X SYBR Green PCR Master Mix (Applied BioSystems, 
Foster City, CA), 15 pmol of each primer, and 10 ng of template DNA were used. 
Standard curves were obtained by harvesting pure cultures of each bacterium in the 
logarithmic growth phase in triplicate to create a five-fold dilution series. DNA from each 
serial dilution was extracted using a PowerSoil DNA Isolation Kit (MO Bio Laboratories, 
Inc) and amplified along with fecal DNA samples using a Taqman ABI PRISM 7900HT 
Sequence Detection System (Applied BioSystems). The colony forming units (CFU) of 
each standard curve serial dilution was determined by plating the Lactobacillus genus on 
Difco Lactobacilli MRS broth (Becton, Dickenson, and Company, Sparks, MD), and 
Bifidobacterium genus on Difco Reinforced Clostridial Medium (Becton, Dickenson, and 
Company). Cycle threshold (Ct) values were plotted against standard curves for 
quantification (CFU/mL) of the target bacterial DNA from fermentation samples. 
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Statistical Analysis  
Statistical analysis was conducted using SAS statistical program software version 9.3 
(SAS Institute, Cary, NC). Analysis of variance (ANOVA) with Tukey pair-wise was 
used for all tests measuring differences of means. Statistical significance was achieved 
for p-values less than 0.05. Log transformations were implemented as needed for 
analysis.  
 
Results 
Gas Production and pH Shift 
Within the first four hours of analysis, neither WD or PHGG produced detectable 
amounts of gas. At 8 hours, PHGG produced significantly more gas (p<0.001) than WD, 
as well as at 12 and 24 hours of fermentation (Figure 2-1). Each fiber produced a  
significant decrease in pH (Table 2-1), with WD decreasing more consistently over 24 
hours, while PHGG decreased quickly between 4 and 8 hours of fermentation, which is 
simultaneously reflected by the large increase in gas production at 8 hours for PHGG.  
 
SCFA Production 
Levels of acetate, propionate and butyrate indicate that increased amounts of SCFAs can 
be seen with time in the batch culture fermentation system for both WD and PHGG. 
Levels for PHGG remained constant or declined after 12 h. All levels expressed (Table 2-
2) are expressed as µmol SCFA/mL of system media.  
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Prebiotic Effects  
Shifts in Bifidobacteria and Lactobacilli were used to demonstrate the prebiotic effects 
measured in the batch culture fermentation system. For both genera of analysis, all three 
samples had similar baseline concentrations. At 12 h WD was slightly more bifidogenic 
than PHGG (p=0.052), and also at 24 h (p=0.043) (Table 2-3). Changes in Lactobacilli at 
12 h and 24 h for both WD and PHGG show that both fibers demonstrate lactogenic 
prebiotic properties. Based on fermentation kinetics, PHGG is more rapidly fermented 
than WD, and both fibers show prebiotic effects, based on changes in Bifidobacteria and 
Lactobacilli, as early as 12 h.     
 
Discussion 
The human gut microflora is a diverse population, with many different genera of bacteria 
having very different influences on the host. Both Lactobacillus and Bifidobacterium are 
generally accepted as two beneficial genera of bacteria, and contribute to a myriad of 
health benefits to the host.6 Mechanisms underlying these benefits are thought to be 
through modulating the immune response, and antagonizing pathogens either by 
production of antimicrobial compounds or through competition for mucosal binding 
sites.153 Additionally, these gut microbes faciliate nutrient and energy extraction from the 
diet.154 Therefore, increasing dietary fiber intake while modulating the gut microbiota 
through supplementation with dietary fibers with prebiotic activity may aid in promoting 
the gut health of the host. Long-term studies have shown that fiber supplementation can 
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alter the makeup of the intestinal microflora with soluble fibers,155 while the purpose of 
this study was to evaluate the early prebiotic effects employing an in vitro model.   
 
Quantitative PCR analysis of WD and PHGG display that both are prebiotic dietary 
fibers, with both fibers displaying bifidogenic and lactogenic properties as early as 12 h 
when compared to baseline measurements. Previous studies have also shown bifidogenic 
and lactogenic properties for WD and PHGG at 24 h, while this is the first study to show 
rapid prebiotic activity at 12 h. Between fibers, WD is more bifidogenic at both 12 h 
(p=0.052) and 24 h (p=0.043) when compared to PHGG, although PHGG still shows 
bifidogenic and lactogenic growth at both 12 h and 24 h. WD has also been shown to 
increase other genera of beneficial bacteria, including non pathogenic Clostridium and 
Roseburia, in similar models.156  
 
Secondary measurements of fermentation kinetics, including change in pH, total gas 
production and development of SCFAs were also key components to modeling the 
mechanism of action for these fibers. For WD and PHGG, pH decreased from baseline 
until the 24 h time point. It is postulated that a decrease in gut pH allows for more 
efficient absorption of specific minerals,157,158 and may provide protective effects in the 
colon. Both fibers did not produce detectable amounts of gas until 8 h, and for the 12 h 
and 24 h measurements, PHGG produced significantly more total gas. Acetate, 
propionate and butyrate are commonly measured SCFAs and are representative end-
products of colonic fermentation and are typically influenced by both microbes present 
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and substrates utilized. Acetate is commonly metabolized by muscles for energy,159 
propionate used as a gluconeogenic substrate160 and butyrate used as an oxidative fuel for 
colonocytes.161 Production of these acidic metabolites also promotes a decrease in colonic 
pH,162 which promotes the growth of many lactic acid bacteria that thrive in more acidic 
environments. Clinical studies have also shown that this decrease in pH promotes growth 
of beneficial bacteria such as Bacteroides and inhibits growth of Clostridum 
perfringens.163 Based on secondary fermentation measurements, PHGG is more rapidly 
fermented than WD.  
 
Because of the rapid formation and absorption of SCFAs in vivo, in vitro models are 
typically employed to accurately understand the kinetics of colonic fermentation. 
Although pooled fecal homogenates were used in this study, stimulation of bifidogenic 
and lactogenic bacteria are consistent with other clinical studies, demonstrating the 
prebiotic effects of WD and PHGG. The current study demonstrates that WD and PHGG 
act as prebiotic fibers and the prebiotic changes can occur as early as 12 hours. Future 
research should be conducted using individual fecal sampling to analyze specie-specific 
stimulation of WD and PHGG, and doing so will allow for accurate comparisons between 
individuals in the population and help us to better understand the relationship between 
fiber consumption, the host’s microbiome and overall digestive health.  
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Table 2-1. pH shift in batch culture fermentation system with WD and PHGG across 24 h 
of analysis. 
Time 
(h) 
pH 
WD PHGG Blank 
0 6.96 (0.02) a 6.97 (0.01) a 7.06 (0.01) b 
4 6.51 (0.00) a 6.59 (0.02) b 6.96 (0.01) c 
8 6.34 (0.00) b 5.93 (0.00) a 6.92 (0.00) c 
12 6.07 (0.01) b 5.90 (0.00) a 6.92 (0.01) c 
24 5.78 (0.02) a 5.86 (0.00) b 6.92 (0.01) c 
* Values are mean (n=3) followed by (SE). 
** Values with different letters are statistically different from each other within rows 
(p<0.05). 
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Figure 2-1. Total gas volume produced in batch culture fermentation system with WD 
and PHGG across 24 h of analyis. 
 
*Columns with different letters are significantly different from one another within the 
same time of measurement (p<0.05), at 8, 12 and 24 h.  
 **Values displayed are mean values (n=3) ± SE. 
***No measurable amounts of gas were detected in the substrate blank, or at 0 h or 4 h 
for WH and PHGG. 
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Table 2-2. SCFAs of exposed human fecal inoculum across 24 h of analysis.  
Time 
(Hours) 
Acetate (µmol/mL) Propionate (µmol/mL) Butyrate (µmol/mL) 
WD PHGG WD PHGG WD PHGG 
0 1.20 (0.05)  1.03 (0.09)  0.69(0.01)  0.68(0.02)  0.98(0.03)  0.95(0.03)  
 
4 5.02 (0.38)  4.30 (0.14)  2.45(0.17)  2.36(0.03)  3.70(0.29)  3.22(0.05)  
 
8 7.56 (0.36)  9.83(0.01)  7.37(0.19)  7.47(0.29)  7.77(0.39)  10.48(0.77)  
 
12 9.71 (0.53)  10.85(0.23)  8.94(0.66)  10.62(0.10)  8.35(0.78)  10.76(0.18)  
 
24 11.60(0.71)  10.74(0.13)  10.59(0.51)  10.62(0.44)  8.32(0.15)  9.85 (0.62)  
*Values are mean (n=3) followed by (SE). 
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Table 2-3. Alterations in the microbiota concentration in batch culture fermentation with 
WD And PHGG after 0, 12 and 24 h of fermentation with human fecal inoculum. 
Time 
(Hours) 
Bifidobacteria 
(CFU log10/mL) 
Lactobacilli  
(CFU log10/mL) 
WD PHGG Blank WD PHGG Blank 
 
0 9.24(0.03)a 9.14(0.07)a 
 
9.08(0.00)a 
 
10.39(0.04)a 10.40(0.09)a 
 
10.35(0.02)a  
12  9.50(0.03)b 9.30(0.04)b 9.05(0.06)a 10.79(0.04)b 10.86(0.07)b 10.35(0.02)a 
24 9.41(0.07)b  9.27(0.04)c 8.96(0.07)a 10.76(0.09)b 10.68(0.04)b  10.23(0.03)a 
*Values displayed are mean (n=2) (standard error). 
**Values with different letters are statistically different from each other within rows of 
three columns displaying data for each respective genus (p<0.05). 
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CHAPTER THREE 
In Vitro Analysis of Partially Hydrolyzed Guar Gum Fermentation Differences Between 
Six Individuals 
The original version of this article can be found at Food & Function 7.4(2016):1833-
1838. The reprint of this article has been used with permission from the publisher, as 
published in agreed format.  
 
Executive Summary 
Partially hydrolyzed guar gum (PHGG) is a fermentable, soluble, non-gelling fiber 
consumed as both a supplement and ingredient. PHGG supports bifidogenic and 
lactogenic growth, and increases the concentration of SCFAs in the distal intestine due to 
its fermentability. Changes in SCFA development due to the fermentation of dietary 
fibers in the colon has been widely studied, but there are limited studies analyzing the 
differences in SCFA development across multiple individuals (ages 23-68) exposed to the 
same dietary fiber (PHGG). With the six donors analyzed in this study, gas production 
varied from 59-80 mL/0.5g fiber at 12 h and 85-93 mL/0.5g fiber at 24 h between the six 
donors. At 12 h butyrate concentrations varied from 6.99 µmol/mL to 23.84 µmol/mL 
and from 8.78 µmol/mL to 22.84µmol/mL at 24 h. Total SCFA concentration at 24 h 
ranged from 42.85 µmol/mL to 91.17 µmol/mL. The overall average ratio for the six 
fecal donors was 30:45:25 (acetate:propionate:butyrate), which is similar to other 
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fermentable fibers analyzed using in vitro systems. SCFA development in the distal 
intestine increases the amount of metabolizable energy from the diet, but varies greatly 
between people based primarily on the composition and changes of their gut microflora. 
With over a 2-fold difference in SCFA production, significant differences were found 
between healthy individuals fecal microflora when exposed to PHGG. Donor 6 SCFA 
concentrations decreased at 24 h, indicating a quicker fermentation process than the other 
five donors. All SCFAs measured fluctuated greatly between the six individuals within 
24 h of analysis.    
 
Introduction 
Dietary fiber consumption in the U.S. is approximately 17 g/d for adults,141 far below the 
recommended 38 g/d and 25 g/d for males and females, respectively.140 The health 
benefits of consuming adequate fiber are quite extensive, including the ability to help 
maintain a healthy body weight,164 increased satiety,165 improved cardiovascular 
health,166,167,168 digestive system health,169 and support beneficial growth of the gut 
microflora.170 An under-researched area is individual variation of fermentation dynamics, 
depending largely on the composition of the host’s gut microflora. Many studies have 
demonstrated that changes in SCFA concentrations are primarily due to fluctuations in 
the host’s bacterial makeup.171–173 
 
Partially hydrolyzed guar gum (PHGG) is a commonly consumed fiber formed from the 
controlled hydrolysis of guar gum, and is composed of mannose and galactose 
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monomers. PHGG has been shown in randomized, cross-over clinical studies to reduce 
hunger while increasing satiety.147,148 PHGG has also been shown to increase levels of 
bifidobacteria and lactobacilli,150,174 two beneficial genera of bacteria. In a clinical 
feeding study, subjects that consumed 20 g/d of PHGG for four weeks showed decreased 
total serum cholesterol, increased fecal weight and output frequency and lower fecal pH 
without influencing fat, protein or mineral absorption.175 PHGG has also been shown to 
alleviate irritable bowel syndrome (IBS) due to its non-gelling capacity and therapeutic 
effects.176  
 
Short-chain fatty acids (SCFA) are commonly measured end-products of colonic 
fermentation. SCFA can contribute between 1.5-2.5 kcal/g,177 contributing up to 10% of 
metabolizable energy (ME) to the diet. Schwiertz et al found that there was a higher 
concentration of SCFAs in overweight and obese individuals.178 Similar studies have 
correlated higher ratios of Firmicutes to Bacteroidetes and increased concentrations of 
SCFAs with obesity.179–181 This increase in metabolizable energy also has many other 
beneficial effects to the consumer.182    
 
SCFAs can act as anti-diarrheal agents by their stimulation of water and sodium 
absorption in the distal intestine, which may be one of the reasons why diarrhea is 
sometimes a consequence of impaired fermentation in the distal intestine. Antibiotics 
sometimes cause diarrhea and have been shown to drastically decrease SCFA 
   45
concentrations in vitro.183 Concentrations and oxidation rates of SCFAs may also play on 
important role in the pathogenesis of colitis.184   
 
The objective of this study was to compare SCFA development among six donor’s fecal 
microflora after exposure to PHGG in an in vitro fermentation system, with the secondary 
measurement of total gas production to analyze the differences in fermentation rates 
within the first 24 h among six individuals. To our knowledge, this is the first study to 
analyze inter-individual fermentation differences among six individuals exposed to 
PHGG within 24 h.   
 
Materials 
Fiber analyzed in this study was partially hydrolyzed guar gum (Benefibra™, Novartis 
Consumer Health Spa Origgio, Varese, Lombardy, Italy). Chemical reagents used were 
provided by ThermoFisher Scientific (ThermoFisher Scientific Inc., Waltham, MN, 
USA), Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA) and Oxyrase (Oxyrase Inc., 
Mansfield, OH, USA).  
 
Methods 
Donor Information 
Demographic characteristics of the six fecal donors (Table 3-1). 
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Fecal Collection 
Fecal samples were collected from six healthy volunteers (5 males, 1 female) under 
anaerobic conditions from individuals (ages 21-68) consuming non-specific Western 
diets, free of any antibiotic treatments in the last year, not affected by any GI diseases and 
not consuming any probiotic or prebiotic supplements. Fecal samples were anaerobically 
collected within 30 minutes of the start of the fermentation, and homogenized 
immediately upon collection. All data and samples collected were done in accordance 
with University of Minnesota policies and procedures.  
 
Fermentation 
Fiber samples (0.5 g) were hydrated in 40 mL of prepared sterile tricase peptone 
fermentation media in 100 mL serum bottles, capped, and incubated for 12 hours at 4°C. 
Following incubation, serum bottles were transferred to a circulating water bath at 37°C 
and allowed to incubate for 2 hours. Post-collection, fecal samples were mixed using a 
6:1 ratio of phosphate buffer solution to fecal sample. After mixing, obtained fecal slurry 
was combined with prepared reducing solution (2.52 g cysteine hydrochloride, 16 mL 1N 
NaOH, 2.56 g sodium sulfide nonanhydride, 380 mL DD H2O) at a 2:15 ratio. 10 mL of 
the prepared fecal inoculum was added to each of the serum bottles, 0.8 mL Oxyrase® 
was added, flushed with CO2, sealed, and then immediately placed in a 37°C circulating 
water bath. Samples were prepared in triplicate and analyzed at 0, 12 and 24 h. Upon 
removal at each time point, total gas volume was measured. Then, 1 mL of copper sulfate 
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(200 g/L) was added to cease fermentation. Lastly, 2 mL aliquots were frozen at -80°C 
for SCFA analysis. 
 
Gas Analysis 
Total gas production was measured by syringe difference analysis. Gas was measured by 
piercing cap of serum bottle with syringe needle and measuring gas released from each 
individual sealed serum bottle. 
 
SCFA Analysis 
SCFA extraction methods were adapted and slightly modified from Schneider et al.151 2 
mL aliquots were removed from the -80°C freezer and placed in a 4°C cooler for 12 
hours prior to analysis. Tubes were then gently vortexed for 5 seconds. Then, 1.6 mL of 
DI H20, 400µL H2SO4 (50% vol/vol), and 2 mL diethyl ether (premixed with 2-ethyl 
butyric acid as internal standard) were all added to tubes and vortexed again for 5 
seconds. Tubes were then placed in an orbital shaker for 45 minutes at 100 RPM. Tubes 
were removed and then centrifuged for 5 minutes at 3000 RPM. The supernatant was 
removed from tube and placed in 10 mL tubes containing CaCl2 to remove residual 
water. The solution was then filtered using a BD 1 mL syringe (Becton, Dickinson and 
Company Franklin Lakes, NJ) and a Millex 13 mm nylon membrane filter with a 0.20 µm 
pore size (Merck Millipore Ltd Tullagreen, Carrigtwohill, Co. Cork, IRL). Extractions 
were then analyzed using a HP 5890 series gas chromatograph (Hewlett Packard, Palo 
Alto, CA) with a 30 m x 0.250 mm x 0.25 µm polyethylene glycol (PEG) column 
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(Agilent Technologies, USA), with a 110°C oven temperature. Samples were injected 
using an automated HP 7673 GC/SFC injector (Hewlett Packard, Palo Alto, CA). Injector 
and detector temperatures were 220°C and 240°C, respectively. Flow rates for air, helium 
and hydrogen were 26, 28 and 315 mL/min, respectively. All samples were analyzed 
utilizing a 50:1 split ratio. 
 
Statistical Analysis  
All statistical analysis was conducted using SPSS (SPSS Chicago, IL). Analysis of 
variance (ANOVA) with Tukey HSD was used for all tests measuring differences among 
means. Log transformations were applied where necessary. Statistical significance was 
achieved for p-values less than 0.05.  
 
Results 
Gas Production 
At 12 h post-inoculation, gas production ranged from 59 mL to 80 mL (Figure 3-1), with 
an overall average production of 74 mL, similar to previously published data.174 At 24 h, 
gas production ranged from 85 mL to 93 mL, with an overall average gas production of 
90.2 mL for the six individuals. Between 12 h and 24 h of analysis the average increase 
in gas production was 16.3 mL, but ranged between 5 mL to 34 mL increases, with all 
individuals having higher gas production at 24 h compared to 12 h.  
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SCFA Production 
Acetate production varied greatly among the six donors, with concentrations increasing at 
24 h compared to 12 h for 5 of the six donors (Figure 3-2). Donor 4 had similar 
concentrations to donor 5 and 6, p=0.343 and p=0.803, respectively, but had the highest 
concentration at 24 h. Although donors 4, 5 and 6 had similar concentrations at 12 h, they 
were all statistically different at 24 h (4 vs. 5, p=0.047; 4 vs. 6, p<0.001; 5 vs. 6, 
p=0.024). At 12 h, donors 1, 2 and 3 had similar concentrations (1 vs. 2, p=0.580; 1 vs. 3, 
p=0.239; 2 vs. 3, p=0.524), and at 24 h both donor 1 and 3 had similar concentrations 
(p=0.305), while donor 2 was significantly lower than both (1 vs. 2, p=0.003; 2 vs. 3, 
p=0.033).  
 
Propionate concentrations (Figure 3-3) closely resemble the acetate concentrations 
(Figure 3-2) in that donors 1, 2 and 3 had the lowest concentrations at 12 and 24 h, and 
donor 4 had the highest concentration at 24 h. At 12 h donor 2 had the lowest 
concentration (2 vs. 1, p<0.001; 2 vs. 3, p=0.012). Donor 2 also had the lowest 
concentration at 24 h, but statistically similar to donor 1 and donor 3, p=0.115 and 
p=0.161, respectively. At 24 h of exposure, donor 4 had the highest concentration (4 vs. 
5, p=0.001; 4 vs. 6, p=0.003).  
 
Butyrate concentrations and changes in concentrations varied greatly among the six 
donors (Figure 3-4). Donor 3 had the lowest butyrate concentration at 12 h (3 vs. 1, 
p=0.048; 3 vs. 2, p=0.003), and at 24 h had statistically similar concentration compared to 
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donor 2 (p=0.455) and a lower concentration than donor 1 (p<0.001). Donor 6 had the 
highest concentration at 12 h (6 vs 5, p=0.009) and had similar concentrations to donors 4 
and 5 at 24 h (6 vs. 5, p=0.288; 6 vs. 4, p=0.166).  
 
Between donor 4 and donor 2 at 24 h of exposure there was over a 2-fold difference in 
total SCFA production (Table 3-2). Donor 6 was the only subject to have a decrease in 
total SCFA at 24 h compared to 12 h. This is likely due to quicker ability to ferment 
PHGG prior to the 12 h measurement. Donor 5 had similar concentrations to donor 6 
(p=0.352) at 12 h and had similar concentrations to donor 6 (p=0.717) at 24 h, but less 
than donor 4 (p=0.028). 
 
Discussion 
In vivo, total SCFA production by humans is usually between 100-200 mM per day, but 
is highly dependent on the host’s environment and availability of substrate for 
fermentation.185 The average total SCFA concentration after 24 h of analysis was 60.3 
mM/L for all six fecal donors in this study. Once produced, over 95% of all SCFAs are 
immediately absorbed, often making them hard to accurately measure in vivo. The three 
most abundant SCFAs (acetate, propionate and butyrate) are commonly formed due to 
the fermentation of non-digestible carbohydrates and proteins. Other acids that escape 
digestion are typically formed due to the breakdown of branched-chain amino acids that 
surpass digestion in the upper gastrointestinal tract typically include: valerate, isovalerate, 
isobutyrate, 2-methyl-butyrate, formate and caproate.186 Acetate is primarily metabolized 
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for energy in the muscles,159 propionate used as a gluconeogenic substrate outside of the 
colon,160 and butyrate as a fuel for colonocytes.161 Typical ratios for 
acetate:propionate:butyrate range from 40:40:20 to 75:15:10, depending on substrate that 
is available for colonic fermentation.186,187 Many studies show that the order of 
concentration typically follows acetate > propionate > butyrate, but actual concentrations 
vary between studies depending on study design.175,188,189 The average approximate ratio 
for this study was 30:45:25, but varied greatly amount the six fecal donors. Although it is 
well accepted that PHGG is extensively fermented in the gut, little data on SCFA 
production with PHGG have been published.  
 
Many studies have analyzed the impact of different fibers and other macronutrients and 
how they affect SCFA production in many in vitro models,190–192 but to our knowledge, 
this is the first that addresses differences among six individuals within 24 h of exposure. 
One of the first in vitro studies to analyze differences for both inter-individual and intra-
individual relationships between SCFA ratios was conducted by Mortensen et al193, and 
showed that there was a significant correlation between substrate analyzed and resulting 
SCFA production, and no significant differences in inter-individual or intra-individual 
comparisons with the three similar donors used in the study. However, six drastically 
different substrates (glucose, wheat bran, pectin, ispaghula, cellulose and albumin) were 
analyzed with only three fecal donors.  
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Total gas production measures gas produced during fermentation, primarily composed of 
CO2, H2, and CH4.194 Previous studies have shown that breath hydrogen and methane 
poorly represent fiber digestion.195 Total gas production potentially indicates overall 
fermentation rates likely to be seen in the gut. Excessive gas production may lead to 
undesirable flatus, abdominal pain and bloating.  
 
Overall, the SCFA profiles for each of the six donors were quite different at 12 and 24 h. 
With an average overall ratio of 30:45:25 (acetate:propionate:butyrate), acetate 
production was slightly less compared to other fermentable fibers in similar in vitro 
models.196 With over a 2-fold change in total SCFA among donors, ratios fluctuated 
greatly among individuals. Donor 6 had concentrations of acetate, propionate and 
butyrate that were lower at 24 h than 12 h for each respective SCFA, and was the only 
donor to have decreased levels for multiple SCFA. With the highest concentrations at 12 
h of propionate and butyrate, and the second highest acetate concentration at 12 h it is 
clear that the PHGG was fermented primarily before the 12 h measurement. Compared to 
the two other males with similar ages and BMI (donors 4 and 5), differences in 
fermentation rates are likely due to differences in the fecal microflora.  
 
In conclusion, the overall average SCFA ratio for the six fecal donors was 30:45:25 
(acetate:propionate:butyrate), which is similar to other fermentable fibers analyzed using 
in vitro systems. At 24 h there was over a 2-fold difference among individuals, indicating 
significant differences among different individuals exposed to PHGG. With one donor 
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displaying decreased concentrations of all SCFA at 24 h compared to 12 h, fecal 
microbiota from select individuals ferment the digestible components of PHGG 
completely within the first 12 h of exposure. Further studies should quantify those 
bacteria that ferment PHGG quicker than others, and correlations between SCFA 
concentration and targeted gut microbiota should be established.  
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Table 3-1. Demographic characteristics of six fecal donors.  
 Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
Age 31 68 60 24 22 21 
Sex Male Male Female Male Male Male 
BMI 23.7 33.6 19.5 26.3 24.7 23.0 
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Figure 3-1. Total gas production comparing differences among six individuals at 12 h and 24 h post-exposure to PHGG.  
 
* Values displayed are means (n=3)  SE for each individual at 12 h and 24 h.  
** Columns with different letters are significantly different from one another within each time of measurement. Histograms with data 
were analyzed using ANOVA with Tukey HSD (p<0.05). 
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Figure 3-2. Acetate production at 12 h and 24 h of fermentation of PHGG by six individuals.  
 
* Values displayed are means (n=3)  SE for each individual at 12 h and 24 h.  
** Columns with different letters are significantly different from one another within each time of measurement. Histograms with data 
were analyzed using ANOVA with Tukey HSD (p<0.05). 
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Figure 3-3. Propionate production at 12 h and 24 h of fermentation of PHGG by six individuals. 
 
* Values displayed are means (n=3)  SE for each individual at 12 h and 24 h.  
** Columns with different letters are significantly different from one another within each time of measurement. Histograms with data 
were analyzed using ANOVA with Tukey HSD (p<0.05). 
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Figure 3-4. Butyrate production at 12 h and 24 h of fermentation of PHGG by six individuals. 
 
* Values displayed are means (n=3)  SE for each individual at 12 h and 24 h.  
** Columns with different letters are significantly different from one another within each time of measurement. Histograms with data 
were analyzed using ANOVA with Tukey HSD (p<0.05). 
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Table 3-2. Average total SCFA profiles (µmol/mL) for six donors at 12 h and 24 h post-
exposure to PHGG treatment. 
Donor 12 h 24 h 
1 43.98(6.21)a 61.17(4.81)b 
2 34.84(0.88)a 42.85(4.71)a 
3 38.57(2.53)a 49.97(3.54)a,b 
4 61.23(4.34)b 91.17(4.47)d 
5 72.43(3.47)b,c 77.73(4.32)c 
6 77.89(2.37)c 75.62(4.36)c 
*Values are means of triplicate determinations (SEM). Means within columns with 
different letters are significantly different from one another. Data were analyzed using 
ANOVA with Tukey HSD (p<0.05).  
**Total SCFA include: acetate, propionate and butyrate.  
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CHAPTER FOUR 
In Vitro Analysis of Partially Hydrolyzed Guar Gum Fermentation on Identified Gut 
Microbiota. 
 
The original version of this article can be found at Anaerobe 42(2016):60-66. The reprint 
of this article has been used with permission from the publisher, as published in agreed 
format.  
 
Executive Summary 
Prebiotic dietary fibers resist digestion in the upper gastrointestinal tract and allow for 
stimulation of bacteria in the distal intestine and colon. Stimulation of bacteria among 
different individuals varies greatly, depending on a wide range of variables. To determine 
the range of differences in response between individuals, a preclinical in vitro 
fermentation was conducted with six fecal donors. The primary objective was to compare 
the fecal microbiota of six individuals at baseline, 12 h and 24 h post-exposure to 
partially hydrolyzed guar gum (PHGG). Fecal donations were collected from six healthy 
individuals consuming a non-specific Western diet, free of antibiotic treatments in the 
past year, not affected by any GI diseases and not consuming any probiotic or prebiotic 
supplements. Fecal samples were exposed to 0.5 g of PHGG and measured for bacterial 
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changes at 0, 12 and 24 h base on 16S rRNA sequencing. Parabacteroides increased 
from 3.48% of sequence reads to 10.62% of sequence reads after 24 h (p = 0.0181) and 
Bacteroidetes increased from 45.89% of sequence reads to 50.29% of sequence reads (p = 
0.0008). PHGG stimulates growth of Parabacteroides, a genus of bacteria that have been 
inversely associated with IBS and ulcerative colitis. PHGG provides stimulation of 
beneficial Bacteroidetes (Bacteroides and Parabacteroides), which may be correlated 
with many positive health markers and outcomes. PHGG is a prebiotic dietary fiber that 
is readily fermentable. 
 
 
Introduction 
Fiber consumption in the U.S. is approximately half of the recommended intake, with the 
average U.S. individual only consuming about 17 g/d.141 Dietary fiber with prebiotic 
capacity offers a healthful, practical way to bridge the gap between consumption and 
recommended intake. Dietary fiber supplements can offer some of the same physiological 
benefits as dietary fiber found intact in foods.197 When consumed in adequate levels, 
dietary fiber has been shown to help maintain a healthy body weight,164 improve 
cardiovascular health,166–168 support overall digestive health,169 and support the overall 
growth of the intestinal microbiota.170 
 
The intestinal microbiota have a tremendous impact on overall health, and have been 
recently shown to have a significant impact on the host’s metabolism, immune system 
capacity and many other pathways affecting overall host health.198–200 Recent studies 
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have also found many associations between many diseases and the host’s microbial 
composition, including: metabolic syndrome, diabetes, and many gastrointestinal 
diseases.201–204 The gut microbiome and it’s correlation to health and disease is a quickly 
revolving, dynamic area of research. Next-generation sequencing and other advanced 
sequencing technologies have provided new insight into this rapidly expanding field, and 
have allowed efficient and effective ways to analyze the thousands of diverse taxa within 
the human gastrointestinal tract.205,206 
 
Partially hydrolyze guar gum (PHGG) is a dietary fiber made from the controlled 
hydrolysis of guar gum, composed of both mannose and galactose monomers, and is 
commonly consumed as both a dietary fiber supplement, as well as in foods. PHGG has 
been shown to alleviate irritable bowel syndrome (IBS) due to its non-gelling effects,176 
and has been shown in randomized, cross-over clinical studies to increase satiety.147,148 In 
a four-week clinical feeding study where participants consumed 20 g/d of PHGG 
researchers found an overall decrease in total serum cholesterol, an increase in fecal 
weight and a lower fecal pH without influencing key nutrient absorption. In vitro models 
have shown that PHGG supports the growth of Bifidobacterium and Lactobacillus, two 
genera of bacteria that have been associated with many health outcomes.174,196 
 
This paper is a follow-up of previously published work from our laboratory that 
evaluated the differences in fermentation rates between six individuals’ fecal microbiota 
all exposed to PHGG in an in vitro fermentation model, with the primary objective of 
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showing the differences in short chain fatty acid (SCFA) synthesis and total gas 
production, and found over a 2-fold difference in total SCFA production in 24 h.207 The 
current study has the objective of determining key changes and individual differences 
among six individual’s fecal microbiota exposed to PHGG in an in vitro fermentation 
model. To the authors’ knowledge, this is the first in vitro model with six individuals to 
show the short-term effects of PHGG on the fecal microbiota. 
 
Materials  
Fiber analyzed in this study was partially hydrolyzed guar gum (Benefibra™, Novartis 
Consumer Health Spa Origgio, Varese, Lombardy, Italy). PHGG is a dietary fiber made 
from the controlled hydrolysis of guar gum from the guar plant Cyamoposis 
tetragonolobus, composed of both mannose and galactose monomers. PHGG is a soluble, 
non-viscous fiber often incorporated into both foods and beverages. Chemical reagents 
used were provided by ThermoFisher Scientific (ThermoFisher Scientific Inc., Waltham, 
MN, USA), Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA) and Oxyrase (Oxyrase 
Inc., Mansfield, OH, USA).  
 
Methods 
Donor Information 
Healthy fecal donors (male and female) were selected to represent a wide range in age 
(21-68) and BMI (19.5-33.6) for representative samples from a population (Table 4-1). 
Donors were selected based on screening questionnaire and previous participation.   
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Fecal Collection 
Fecal samples were collected from six healthy volunteers (5 males, 1 female) under 
anaerobic conditions from individuals (ages 21-68) consuming non-specific Western 
diets, free of any antibiotic treatments in the last year, not affected by any GI diseases and 
not consuming any probiotic or prebiotic supplements. Fecal samples were anaerobically 
collected within 10 minutes of the start of the fermentation, and homogenized 
immediately upon collection. All data and samples collected were done in accordance 
with University of Minnesota policies and procedures.  
 
Fermentation 
Fiber samples (0.5 g) were hydrated in 40 mL of prepared sterile tricase peptone 
fermentation media in 100 mL serum bottles, capped, and incubated for 12 hours at 4°C. 
Following incubation, serum bottles were transferred to a circulating water bath at 37°C 
and allowed to incubate for 2 hours. Post-collection, fecal samples were mixed using a 
6:1 ratio of phosphate buffer solution to fecal sample. After mixing, obtained fecal slurry 
was combined with prepared reducing solution (2.52 g cysteine hydrochloride, 16 mL 1N 
NaOH, 2.56 g sodium sulfide nonanhydride, 380 mL DD H2O) at a 2:15 ratio. 10 mL of 
the prepared fecal inoculum was added to each of the serum bottles, 0.8 mL Oxyrase® 
was added, flushed with CO2, sealed, and then immediately placed in a 37°C circulating 
water bath. Samples were prepared in triplicate and analyzed at 0, 12 and 24 h. Upon 
removal at each time point, total gas volume was measured. Then samples were divided 
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into aliquots for analysis and 1 mL of copper sulfate (200 g/L) was added to cease 
fermentation. All samples were immediately frozen and stored at -80°C for further 
analysis.  
 
DNA Extractions 
Fecal bacteria DNA from the in vitro system were extracted using a PowerSoil DNA 
Isolation Kit (MO BIO Laboratories, Inc.) following provided operating instruction, 
including bead beating for 20 min. 
 
Primary/Secondary PCR Amplification 
The V1-V3 region of the 16S rRNA was amplified using a two-step PCR protocol. The 
primary amplification was done using an ABI7900 qPCR machine. The following recipe 
was used: 3 μl template DNA, 0.48 μl nuclease-free water, 1.2 μl 5x KAPA HiFi buffer 
(Kapa Biosystems, Woburn, MA), 0.18 μl 10 mM dNTPs (Kapa Biosystems, Woburn, 
MA), 0.3 μl DMSO (Fisher Scientific, Waltham, MA), 0.12 μl ROX (25 μM) (Life 
Technologies, Carlsbad, CA), 0.003 μl 1000x SYBR Green, 0.12 μl KAPA HiFi 
Polymerase (Kapa Biosystems, Woburn, MA), 0.3 μl forward primer (10 μM), 0.3 μl 
reverse primer (10 μM). Cycling conditions were: 95°C for 5 minutes, followed by 20 
cycles of 98°C for 20 seconds, 55°C for 15 seconds, and 72°C for 1 minute. The primers 
for the primary amplification contained both 16S-specific primers (V1_27F and 
V3_V34R), as well as adapter tails for adding indices and Illumina flow cell adapters in a 
secondary amplification. The following primers were used (16S-specific sequences in 
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bold): Meta_V1_27F 
(TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGAGTTTGATCMTGGCT
CAG) and Meta_V3_534R 
(GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATTACCGCGGCTGCTG
G). 
The amplicons from the primary PCR were diluted 1:100 in sterile, nuclease-free water, 
and a second PCR reaction was set up to add the Illumina flow cell adapters and indices. 
The secondary amplification was done on a fixed block BioRad Tetrad PCR machine 
using the following recipe: 5 μl template DNA, 1 μl nuclease-free water, 2 μl 5x KAPA 
HiFi buffer (Kapa Biosystems, Woburn, MA), 0.3 μl 10 mM dNTPs (Kapa Biosystems, 
Woburn, MA), 0.5 μl DMSO (Fisher Scientific, Waltham, MA) 0.2 μl KAPA HiFi 
Polymerase (Kapa Biosystems, Woburn, MA), 0.5 μl forward primer (10 μM), 0.5 μl 
reverse primer (10 μM). Cycling conditions were: 95°C for 5 minutes, followed by 10 
cycles of 98°C for 20 seconds, 55°C for 15 seconds, 72°C for 1 minute, followed by a 
final extension at 72°C for 10 minutes. The following indexing primers were used (X 
indicates the positions of the 8 bp indices): Forward indexing primer: 
AATGATACGGCGACCACCGAGATCTACACXXXXXXXXTCGTCGGCAGCGTC 
and Reverse indexing primer: 
CAAGCAGAAGACGGCATACGAGATXXXXXXXXGTCTCGTGGGCTCGG  
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Normalization and Sequencing 
The samples were normalized using a SequalPrep capture-resin bead plate (Life 
Technologies, Carlsbad, CA) and pooled using equal volume. The final pools were 
quantified via PicoGreen dsDNA assay (Life Technologies, Carlsbad, CA) and diluted to 
2nM. 10 μl of the 2 nM pool was denatured with 10 μl of 0.2 N NaOH, diluted to 8 pM in 
Illumina’s HT1 buffer, spiked with 15% phiX, heat denatured at 96°C for 2 minutes, and 
sequenced using a MiSeq 600 cycle v3 kit (Illumina, San Diego, CA). 
 
Sequence Processing and Analysis 
Generated sequence data was processed and analyzed using QIIME.208 Fastq sequence 
data was processed with the University of Minnesota’s gopher-pipeline for 
metagenomics, and automated pipeline for high-throughput sequence data sets.209 
Sequence data had adapters removed and sliding quality trimming window by 
Trimmomatic210; primers removed and overlapping reads merged by Pandaseq.211 Within 
QIIME, chimera checking done by chimera slayer, Open reference OTU picking 
completed with Usearch61, taxonomic identification using GreenGenes (Version 13.8) 
reference database, rarefied to 14,393 sequences per sample. Analysis was performed 
using R (R Development Core Team, 2012). 
 
Statistical Analysis 
All statistical analysis was performed using R software (R Development Core Team, 
2012). Differences in means were determined using the Kruskal-Wallis ANOVA test 
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(data determined non-parametric with QIIME), testing the null hypothesis that the 
location parameter of the groups of abundances for a given operational taxonomic units 
(OTU) is the same. Multiple comparisons were corrected using the FDR procedure. 
Significance was set for p-values <0.05.  
 
Consent 
Voluntary informed consent was obtained from all fecal donors prior to this study 
according to University of Minnesota policies and procedures.  
 
Results 
Sequencing of the 16S rRNA gene was conducting using Illumina MiSeq 2000 
sequencing platforms at the University of Minnesota Genomics Center. From the 6 fecal 
samples analyzed from the in vitro system across 24 h of fermentation (6 fecal samples x 
3 time points x 3 technical replicates = 54 samples analyzed), there were >30 million 
total sequences generated, representing 11 bacteria phyla and 416 OTUs at a 97% 
similarity threshold. Changes in fecal microbiota were analyzed for all six fecal donors in 
the in vitro fermentation system at baseline, 12 and 24 h. Taxa with greater than 0.05% 
overall abundance were summarized (Table 4-2). At baseline, Bacteroidetes and 
Firmicutes were the most abundant phyla of bacteria, consisting of approximately 90% of 
all sample reads. Proteobacteria was the third most abundant phyla identified, consisting 
of approximately 4% of the sample reads. Actinobacteria and Verrucomicrobia accounted 
for less than 1% of all sequence reads.  
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Across the 24 h of analysis, overall abundance of sequences of Bacteroidetes increased 
significantly (p<0.001) from approximately 45.9% of sequence reads at baseline to 
approximately 50.3% of sequences at 24 h. Firmicutes accounted for approximately 
44.9% of total sequences at baseline, which decreased to 40.4% of sequence reads at 24 h 
(p = 0.0527), trending towards significance. Verrucomicrobia accounted for 0.51% of 
sequence reads at baseline, and increased significantly over 24 h to 0.82% of sequence 
reads at 24 h (p<0.001), although still accounted for less than 1% of all sequence reads. 
Similar shifts in abundant phyla identified were similar for all fecal donors (Figure 4-1). 
 
At the genus level, Bacteroides was the most abundant genus in all samples, consisting of 
27.1% of sequence reads at baseline, which increased to 33.05% of all reads at 24 h (p = 
0.14) (Table 4-2). Parabacteroides had the greatest stimulation, increasing from 3.48% 
of sequence reads at baseline to 10.18% of sequence reads at 12 h and 10.62% at 24 h (p 
= 0.0181).  Odoribacter decreased significantly from baseline compared to 24 h of 
fermentation, decreasing from 0.54% at baseline to 0.18% after 24 h of fermentation (p = 
0.002).  Phascolarctobacterium increased significantly from 0.51% at baseline to 2.31% 
after 24 h (p = 0.0011). The 19 most abundant genera of bacteria composed >99% of all 
sequences analyzed (Figure 4-2), which we identified in all 6 fecal donors.  
 
Comparing ratios of Bacteroidetes:Firmucutes, each individual’s fecal microbiota 
responded much differently to PHGG  after 12 h and 24 h post-exposure (Figure 4-3). 
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The average percent reads of Firmicutes at baseline was 44.87% of total reads, although 
this varied greatly from donor to donor, from as low as 29% of total reads, to as high as 
47%. After 12 h of fermentation, some donors’ microbiota populations of Firmicutes 
increased, while some decreased as much as 10% and some were unaffected. Firmicutes 
and Bacteroidetes population fluctuations were primarily specific to each donor, with 
some overall similar trends.  
 
Differences in analyzed microbiota were analyzed between donors and across reference 
fermentation time points. The Unweighted Unifrac beta diversity PCoA plot, measuring 
dissimilarity between all sequence reads based their generated 99% OTU composition, 
showed that across all measured time points that samples were most similar to each 
donor, and not their time of analysis (Figure 4-4). Donors 1-3 (ages 31-68) were also 
more similar to one another than donors 4-6 (ages 21-24).  
 
Discussion 
The increase of Parabacteroides was the most significant increase among all identified 
taxa, increasing from 3.48% of sequence reads at baseline to 10.62% of sequence reads 
after 24 h of fermentation. In a clinical study, oral administration of P. distasonis has 
been shown to reduce severity of intestinal inflammation in induced acute and chronic 
colitis in murine models due to the modulation of both immunity and microbiota 
factors.212 Parabacteroides has been identified as one of the most abundant genera of 
bacteria in the human gastrointestinal tract.213 Parabacteroides has also been shown to be 
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present in higher concentrations in healthy controls compared to patients with IBS or 
ulcerative colitis, and it has been speculated that this genera of bacteria may play an 
influential role in the pathogenesis of both diseases.214 Parabacteroides stimulation has 
been considered to have a prebiotic effect due to their preference to perform saccharolytic 
activity instead of proteolytic activity.170,215 
 
PHGG has been extensively reviewed for the treatment of IBS.216,217 Briefly, PHGG has 
been shown to offer prebiotic activity due to its increase in colonic SCFA production and 
stimulation of Lactobacillus and Bifidobacterium 218,219 in two studies utilizing culture-
dependent and florescent in situ hybridization (FISH) methods. Baseline Bifidobacterium 
and Lactobacillus sequence reads were less than 0.01% of all sequence reads for each 
respective genus in all six donors. Low bifidobacteria and lactobacilli counts could be 
due to a wide variety of influential factors (age, stress, environmental components)106–110 
or potentially due to the age of fecal donors.110 Other studies have found bifidobacteria to 
be found in very low quantities, if found at all.121,122 Metagenomic 16S rRNA studies 
have often found under representation of bifidobacteria due to potential biases in PCR 
primers and amplification, and have found potential solutions using cpn60-based 
methods.220 Because of the low concentrations of these genera of bacteria in most 
populations, it is imperative to analyze other abundant taxa of bacteria using next-
generation sequencing methods. PHGG fermentation often doesn’t support growth of 
these genera of bacteria in in vitro models because it is the degraded products of PHGG 
that support growth of these bacteria, which aren’t formed in in vitro models.219 PHGG is 
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enzymatically broken down into low molecular weight galactomannan, which is the 
primary carbon source for intestinal bacteria.221–223 Galactomannan formation from 
PHGG consists of a mannose backbone with galactose side groups (mannose:galactose ~ 
2:1).224 
 
Odoribacter, Butyricimonas,  Faecalibacterium,  Lachnospira, Turicibacter, Bilophila 
and  Akkermansia populations all significantly decreased after 24 h of exposure to PHGG 
(p<0.05). Parabacteroides and Phascolarctobacterium populations significantly 
increased after exposure to PHGG (p<0.05). These shifts in targeted genera allowed for a 
significant change in the ratio of Bacteroidetes:Firmicutes. The overall abundance of 
Firmicutes decreased from 44.87% of sequence reads at baseline to 40.43% of sequence 
reads after 24 h (p = 0.0527). Bacteroidetes increased from 44.89% of sequence reads at 
baseline to 50.29% of sequence reads after 24 h (p = 0.0008).    
 
Various mouse models have shown lean mice to have increased ratios of 
Bacteroidetes:Firmicutes compared to obese mice.225,226 In human intervention studies, 
similar increased ratios of Bacteroidetes:Firmicutes have been seen following weight 
loss,227 although have been contradicted elsewhere.228 A recent study has also shown 
increased proportions of Bacteroidetes:Firmicutes ratios with fiber supplementation, 
independent of caloric restriction, which was associated with total fiber intake and not 
BMI.229 PHGG, along with many other types of dietary fiber, may offer feasible ways to 
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increase Bacteroidetes in healthy individuals, although the precise function of these 
bacteria still remains largely unclear.  
 
In conclusion, PHGG offers similar bacterial stimulation as other dietary fibers, most 
notably similar in the stimulation of Parabacteroides and Bacteroidetes. PHGG is a 
fermentable, versatile fiber that can be used in many applications as a way to help 
consumers bridge the gap between recommended intake and actual fiber intake, 
especially for consumers with IBS or related issues, as PHGG supplementation has been 
shown to alleviate IBS symptoms. PHGG offers stimulation of beneficial bacteria and 
produces significant amounts of SCFA within 24 h of exposure to microbiota, thus 
displaying effective prebiotic properties, and potentially therapeutic effects. 
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Table 4-1. Demographic characteristics of six fecal donors.  
 Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
Age 31 68 60 24 22 21 
Sex Male Male Female Male Male Male 
BMI 23.7 33.6 19.5 26.3 24.7 23.0 
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Table 4-2. Combined changes across 24 h of fermentation for identified abundant taxa. 
Samples were analyzed between differentially represented OTUs for significant overall 
changes, not between any two time points.   
Targeted Taxa 
(Phlyum and Genus) Baseline 12 h 24 h p-value 
Actinobacteria 0.97 0.79 1.77 0.1294 
Collinsella 0.78 0.68 1.64 0.0986 
Adlercreutzia 0.03 0.02 0.02 0.6104 
Bacteroidetes 45.89 52.32 50.29 0.0008 
 Bacteroides 27.12 36.13 33.05 0.1455 
 Parabacteroides 3.48 10.18 10.62 0.0181 
 Prevotella 0.83 0.30 0.18 0.6385 
 Odoribacter 0.53 0.14 0.18 0.0002 
 Paraprevotella 0.21 0.04 0.01 0.9877 
 YRC22 0.18 0.03 0.02 0.6477 
 Butyricimonas 0.13 0.03 0.04 0.0323 
Firmicutes 44.87 39.33 40.43 0.0527 
 Blautia 2.48 1.34 1.32 0.1763 
 Faecalibacterium 1.59 1.10 0.93 0.0043 
 Ruminococcus 1.52 1.78 2.12 0.9829 
 Coprococcus 0.77 0.78 0.55 0.2631 
 Oscillospira 0.74 0.57 0.63 0.2303 
 Lachnospira 0.55 0.08 0.09 <0.0001 
   Phascolarctobacterium 0.51 2.32 2.31 0.0011 
 Dorea 0.27 0.13 0.27 0.0535 
 Streptococcus 0.19 0.06 0.07 0.0590 
 Dialister 0.18 0.14 0.16 0.5368 
 Clostridium 0.16 0.06 0.06 0.1235 
 Eubacterium 0.13 0.45 0.68 0.2619 
 Veillonella 0.12 0.07 0.08 0.6247 
 Ruminococcus 0.11 0.08 0.11 0.4163 
 Catenibacterium 0.08 0.17 0.16 0.5981 
 Roseburia 0.08 0.12 0.06 0.0906 
 Turicibacter 0.08 0.01 0.02 0.0239 
 SMB53 0.07 0.02 0.03 0.1632 
 Anaerostipes 0.06 0.75 0.94 0.9189 
Proteobacteria 4.09 5.64 5.62 0.5850 
 Sutterella 2.36 3.97 3.60 0.6508 
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 Bilophila 0.14 0.05 0.08 <0.0001 
 Haemophilus 0.10 0.05 0.03 0.0744 
 Oxalobacter 0.06 0.009 0.01 0.2984 
Verrucomicrobia 0.51 0.90 0.81 <0.0001 
 Akkermansia 2.52 0.58 0.56 <0.0001 
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Figure 4-1. Identified abundant phyla based on percent of sequence reads at 0, 12 and 24 
h of fermentation of PHGG for six fecal donors. Specified genera consisted of >99% of 
all sample reads for each individual donor. Technical replicates listed for each fecal 
donor at each specified time of analysis.  
 
*PHGG (partially hydrolyzed guar gum) 
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Figure 4-2. Identified abundant genera at 0, 12 and 24 h of fermentation of PHGG for six 
fecal donors. Specified genera consisted of >99% of all sample reads for each individual 
donor. Technical replicates listed for each fecal donor. 
 
*PHGG (partially hydrolyzed guar gum) 
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Figure 4-3. Fluctuations in ratios of Bacteroidetes:Firmicutes at 0, 12 and 24 h of analysis 
based on percentage of total sequence reads for six fecal donors analyzed. Red (0 h), 
green (12 h) and blue (24 h) indicate length of sample fermentation in vitro.  
 
 
 
 
 
 
 
   80
Figure 4-4. Principal coordinates analysis (PCoA) of analyzed bacterial composition of 
donor samples, including 0, 12 and 24 h samples for all donors. Identifications displayed 
as Unweighted Unifrac distances among all samples for respective donors displayed 
based on their generated 99% OTU composition. 
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CHAPTER FIVE 
Comparing The Prebiotic Effects of Five Common Dietary Fibers. 
 
Executive Summary 
Prebiotic dietary fiber supplements are commonly consumed to help meet fiber 
recommendations and improve gastrointestinal health. Stimulation of beneficial bacteria 
varies greatly between individuals and between products. Prebiotic dietary fibers also 
produce short-chain fatty acids, molecules beneficial to host health. The objective of this 
research project was to compare potential prebiotic effects between six commonly 
consumed fibers using an in vitro fermentation system. The primary objective was to 
measure changes in identified fecal microbiota, with secondary objectives measuring 
total gas production and formation of common short-chain fatty acids. Fecal donations 
were collected from 3 healthy volunteers consuming non-specific Western diets, free of 
antibiotic treatment and supplements. Fibers analyzed included: pure beta-glucan, 
Oatwell (a commercially available oat-bran containing 22% high molecular weight oat β-
glucan, xylooligosaccharides (XOS), WholeFiber (a dried Chicory Root containing 
inulin, pectin, and hemi/celluloses), and pure inulin. Oatwell stimulated the highest 
production of propionate at 12 h (4.76 μmol/mL) compared to inulin, WholeFiber and 
XOS samples (p<0.03). Its effect were similar to those of the pure beta-glucan samples. 
Oatwell and pure beta glucan samples promoted the highest mean propionate production 
at 24 h. XOS resulted in a significant increase in the genus Bifidobacterium after 24 h of 
fermentation (0 h: 0.67 OTUs; 24 h: 5.22 OTUs; p = 0.038). Inulin and WholeFiber 
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increased the beneficial genus Collinsella, consistent with findings in clinical studies. All 
studied prebiotic dietary fibers studied promoted the formation of beneficial markers due 
to fermentation of each specific compound. All compounds provided different, significant 
fermentation patterns, and all provided beneficial effects that would promote host health 
in vivo. 
 
Introduction 
Prebiotic definitions vary among different scientific and political arenas across the 
world.230 Depending on the local definition, nearly all prebiotics can be classified as 
dietary fiber, but not all fibers are considered prebiotics.16 The most recent definition 
describes a prebiotic as “a selectively fermented ingredient that results in specific 
changes in the composition and/or activity of the gastrointestinal microbiota, thus 
conferring benefit(s) upon host health”.15 Functional characteristics of prebiotics include 
the ability to: resist the low pH of the stomach, resist hydrolysis by mammalian enzymes, 
resist absorption in the upper gastrointestinal tract, the ability to be fermented by 
intestinal microbiota and selectively stimulate the growth and/or activity of intestinal 
bacteria associated with host health and overall well-being.13,14 Inulin, beta-glucans, and 
xylooligosaccharides (XOS) all provide health benefits to consumers that are related to 
the fermentation of these compounds in the distal gastrointestinal tract, and are also 
considered functional fibers with many other benefits.6 As the definition of “prebiotic” 
broadens to include the overall impact from the metabolism from these compounds, the 
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category of prebiotics will expand.231 The importance of displaying direct health benefits 
due to bacterial fermentation is still the driving mechanism for all prebiotics.    
 
As our awareness and understanding of the importance of the gut microbiome and gut 
microbiota increases, it’s imperative for consumers to understand the key differences 
between different forms of prebiotics, and where they can be found in various foods and 
food products. XOS is an emerging prebiotic with well-displayed, consistent health 
benefits232 and is composed of sugar oligomers composed of xylose units,233 found 
naturally in fruits, vegetables, milk, honey and bamboo shoots. XOS is commonly 
produced from xylan containing lignocellulosic materials through various chemical 
methods, direct enzymatic hydrolysis, or a combination of both treatments.234–238 Inulin is 
a heterogeneous blend of fructose polymers (DP<10)239 which occurs naturally in 
thousands of plant species, including wheat, onion, bananas, garlic and chicory.240 Beta-
glucan is a polysaccharide composed of D-glucose monomers with beta-glycosidic 
linkages, present in either linear chains in grains, such as oat and barley (up to 7%), or in 
branched structures in fungi, yeast and certain bacteria.241 These prebiotics, or prebiotic 
mixtures, each provide a unique carbon source for selective stimulation of different 
bacterial taxa and are important microbiota-shaping compounds.  
 
Because no analytical method currently exists to measure the prebiotic capacity of foods 
in terms of their influence on gastrointestinal taxa, this field relies heavily on fecalbiotics 
(living or once living fecal microbial populations) to quantify the effects of these 
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compounds. In vitro fermentation models allow for quantitative analysis of specific 
materials and are semi-representative models of colonic fermentation.242 Although not a 
complete substitute for human studies, when paired with in vivo models, in vitro analysis 
can be an accurate systematic approach to analyze different parameters and end points in 
colonic fermentation.243  
 
The objective of this project was to compare currently available prebiotics by their ability 
to change specific taxa as well as compare differences in the production of gas and 
common short chain fatty acids (SCFA) between these products. Inulin, XOS and beta-
glucan based products were chosen for this experiment because they are established and 
emerging prebiotics that are commonly consumed, and offer well-demonstrated health 
benefits to their consumers. 
 
Methods 
Prebiotic Dietary Fibers Analyzed  
The established and emerging prebiotic dietary fibers with well-demonstrated health 
benefits included in this study are all shown in Table 5-1.  
 
Fecal Collection & Donor Information 
Fecal samples were collected from three healthy volunteers (2 males, 1 female) under 
anaerobic conditions from individuals (ages 22-28) consuming non-specific Western 
diets, free of any antibiotic treatments in the last year, non-smokers, not affected by any 
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known GI diseases and not consuming any supplements (Table 5-2). Fecal samples were 
anaerobically collected within 5 minutes of the start of the fermentation, and 
homogenized immediately upon collection. All data and samples collected were done in 
accordance with University of Minnesota policies and procedures. 
 
Fermentation 
Fiber samples (0.5 g) were hydrated in 40 mL of prepared sterile tricase peptone 
fermentation media in 100 mL serum bottles, capped, and incubated for 12 hours at 4°C. 
Following incubation, serum bottles were transferred to a circulating water bath at 37°C 
and allowed to incubate for 2 hours. Post-collection, fecal samples were mixed using a 
6:1 ratio of phosphate buffer solution to fecal sample. After mixing, obtained fecal slurry 
was combined with prepared reducing solution (2.52 g cysteine hydrochloride, 16 mL 1N 
NaOH, 2.56 g sodium sulfide nonanhydride, 380 mL DD H2O) at a 2:15 ratio. 10 mL of 
the prepared fecal inoculum was added to each of the serum bottles, 0.8 mL Oxyrase® 
was added, flushed with CO2, sealed, and then immediately placed in a 37°C circulating 
water bath. Samples were prepared in triplicate and analyzed at 0, 12 and 24 h. Upon 
removal at each time point, total gas volume was measured (by syringe difference 
analysis). Then samples were divided into aliquots for analysis and 1 mL of copper 
sulfate (200 g/L) was added to cease fermentation. All samples were immediately frozen 
and stored at -80°C for further analysis. 
 
SCFA Analysis 
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SCFA samples were extracted according to Schneider et al151 with minor modifications, 
and analyzed with previously described methods.244 
 
 
DNA Extractions 
Fecal bacteria DNA from the in vitro system were extracted using a PowerSoil DNA 
Isolation Kit (MO BIO Laboratories, Inc.) following the provided operating instruction, 
including bead beating for 20 min. 
 
Primary/Secondary Amplification 
The V1-V3 region of the 16S rRNA was amplified using a two-step PCR protocol. The 
primary amplification was done using an ABI7900 qPCR machine. The following recipe 
was used: 3 μl template DNA, 0.48 μl nuclease-free water, 1.2 μl 5x KAPA HiFi buffer 
(Kapa Biosystems, Woburn, MA), 0.18 μl 10 mM dNTPs (Kapa Biosystems, Woburn, 
MA), 0.3 μl DMSO (Fisher Scientific, Waltham, MA), 0.12 μl ROX (25 μM) (Life 
Technologies, Carlsbad, CA), 0.003 μl 1000x SYBR Green, 0.12 μl KAPA HiFi 
Polymerase (Kapa Biosystems, Woburn, MA), 0.3 μl forward primer (10 μM), 0.3 μl 
reverse primer (10 μM). Cycling conditions were: 95°C for 5 minutes, followed by 20 
cycles of 98°C for 20 seconds, 55°C for 15 seconds, and 72°C for 1 minute. The primers 
for the primary amplification contained both 16S-specific primers (V1_27F and 
V3_V34R), as well as adapter tails for adding indices and Illumina flow cell adapters in a 
secondary amplification. The following primers were used (16S-specific sequences in 
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bold): Meta_V1_27F 
(TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGAGTTTGATCMTGGCT
CAG) and Meta_V3_534R 
(GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATTACCGCGGCTGCTG
G). 
The amplicons from the primary PCR were diluted 1:100 in sterile, nuclease-free water, 
and a second PCR reaction was set up to add the Illumina flow cell adapters and indices. 
The secondary amplification was done on a fixed block BioRad Tetrad PCR machine 
using the following recipe: 5 μl template DNA, 1 μl nuclease-free water, 2 μl 5x KAPA 
HiFi buffer (Kapa Biosystems, Woburn, MA), 0.3 μl 10 mM dNTPs (Kapa Biosystems, 
Woburn, MA), 0.5 μl DMSO (Fisher Scientific, Waltham, MA) 0.2 μl KAPA HiFi 
Polymerase (Kapa Biosystems, Woburn, MA), 0.5 μl forward primer (10 μM), 0.5 μl 
reverse primer (10 μM). Cycling conditions were: 95°C for 5 minutes, followed by 10 
cycles of 98°C for 20 seconds, 55°C for 15 seconds, 72°C for 1 minute, followed by a 
final extension at 72°C for 10 minutes. The following indexing primers were used (X 
indicates the positions of the 8 bp indices): Forward indexing primer: 
AATGATACGGCGACCACCGAGATCTACACXXXXXXXXTCGTCGGCAGCGTC 
and Reverse indexing primer: 
CAAGCAGAAGACGGCATACGAGATXXXXXXXXGTCTCGTGGGCTCGG  
Normalization and Sequencing 
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The samples were normalized using a SequalPrep capture-resin bead plate (Life 
Technologies, Carlsbad, CA) and pooled using equal volume. The final pools were 
quantified via PicoGreen dsDNA assay (Life Technologies, Carlsbad, CA) and diluted to 
2nM. 10 μl of the 2 nM pool was denatured with 10 μl of 0.2 N NaOH, diluted to 8 pM in 
Illumina’s HT1 buffer, spiked with 15% phiX, heat denatured at 96°C for 2 minutes, and 
sequenced using a MiSeq 600 cycle v3 kit (Illumina, San Diego, CA). 
 
Sequence Processing and Analysis 
Generated sequence data was processed and analyzed using QIIME208. Fastq sequence 
data was processed with the University of Minnesota’s gopher-pipeline for 
metagenomics.209 Sequence data had adapters removed and sliding quality trimming 
window by Trimmomatic210; primers removed and overlapping reads merged by 
Pandaseq.211 Within QIIME, chimera checking done by chimera slayer, Open reference 
OTU picking completed with Usearch61, taxonomic identification using GreenGenes 
(Version 13.8) reference database, rarefied to 14,393 sequences per sample. Analysis was 
performed using R (R Development Core Team, 2012). 
 
Statistical Analysis 
All statistical analysis was performed using R software (R Development Core Team, 
2012). Differences in means were determined using the Kruskal-Wallis ANOVA test, 
testing the null hypothesis that the location parameter of the groups of abundancies for a 
given OTU is the same. Multiple comparisons were corrected using the FDR procedure. 
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For gas and SCFA data, ANOVA with Tukey HSD was used to compare means. 
Significance was set for p-values < 0.05 for all statistical tests. Replicates (3) for donors 
(3) within treatments groups were separate in vitro fermentations, resulting in a n=9 for 
each treatment group, at each time point of analysis.  
 
Consent 
Voluntary informed consent was obtained from all fecal donors prior to this study 
according to University of Minnesota policies and procedures.  
 
Results 
Gas Production 
At 12 h, the OatWell and the pure beta-glucan samples produced similar amounts of total 
gas (Figure 5-1). The XOS samples produced significantly more gas than the pure beta 
glucan samples (p < 0.01) or the OatWell samples (p < 0.01). The WholeFiber and pure 
inulin samples produced similar amounts of total gas (p = 0.102), and the total gas 
production for both of these prebiotic dietary fibers was significantly higher than for the 
XOS samples, (p < 0.01 and p = 0.045), respectively. At 24 h, the OatWell samples had 
the lowest gas production (46.2 mL) and were similar to the pure beta-glucan samples 
(63.7 mL; p = 0.498). The 24 h XOS samples (74.0 mL) were also similar to the beta-
glucan samples (p = 0.926). However, the 24 h WholeFiber (109.6 mL) and pure inulin 
(107.1 mL) samples produced significantly more gas than XOS, beta-glucan and Oatwell 
samples (p < 0.01).   
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SCFA Production 
For all SCFA analysis, analyses at 12 and 24 h were for production only, from baseline 
corrected samples. Acetate, propionate and butyrate production is shown as μmol/mL of 
fermentation media.  
 
Acetate production at 12 h was similar for the Oatwell, WholeFiber and beta-glucan 
samples (Figure 5-2). The XOS samples produced significantly more acetate at 12 h than 
the Oatwell, WholeFiber or beta-glucan samples (p<0.05). The inulin samples had similar 
amounts of acetate compared to the WholeFiber and XOS samples, and significantly 
more than the Oatwell (p=0.024) and beta-glucan (p=0.013) samples at 12 h. After 24 h 
of fermentation (Figure 5-3), the inulin samples contained less acetate than the XOS 
samples (p=0.038), while the Oatwell, WholeFiber and beta-glucan samples were similar 
to both the XOS and inulin samples.  
 
Propionate production at 12 h of fermentation was highest for the OatWell samples (4.76 
μmol/mL) and was significantly greater than the WholeFiber (p=0.029), XOS (p=0.005) 
and inulin samples (p=0.004), and similar to the beta-glucan samples (Figure 5-4). At 24 
h of fermentation, the Oatwell samples had the highest mean production 5.05 μmol/mL, 
which was significantly greater than the XOS samples (2.58 μmol/mL; p=0.021), and 
similar to WholeFiber, inulin and beta-glucan samples (Figure 5-5).  
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Butyrate production after 12 h of fermentation ranged from 7.30 μmol/mL for the beta-
glucan samples to 16.76 μmol/mL for the inulin samples (Figure 5-6). The inulin samples 
had the highest average production, and were similar to the XOS (16.38 μmol/mL) and 
WholeFiber samples (12.89 μmol/mL). The XOS samples were significantly higher than 
the Oatwell (p=0.035) and beta-glucan samples (p=0.014). At 24 h of fermentation, all 
five prebiotic dietary fibers were statistically similar to one another, ranging from 7.93 – 
14.08 μmol/mL due to a wide ranges in response differences between the three fecal 
donors used in this study (Figure 5-7).  
 
Microbiota Analysis 
DNA extracts from in vitro samples were sequenced using the MiSeq Illumina platforms, 
generating a total of 31,591,899 sequence reads. Sequencing parameters identified reads 
belonging to 11 bacterial phyla, 61 families and 97 genera.  
For all three donors, the phyla Bacteroidetes and Firmicutes represented >80% of all 
sequence reads (Figure 5-8) across 24 h of fermentation. At the family level, 13 families 
represented 85% of all sequence reads (Figure 5-9), while 11 genera represented >75% of 
all sequence reads (Figure 5-10). Six metrics measuring α-diversity for all donors showed 
various degrees of grouping by donors (Figure 5-11), and by treatment group (Figure 5-
12). Both Unifrac and Bray-Curtis β-diversity metrics (measuring pairwise dissimilarity 
between samples), showed similarity among technical replicates of treatment groups for 
each donor (Figure 5-13) as well as for all treatment groups for each respective donor 
(Figure 5-14).  
   92
 
After 24 h of fermentation, the Oatwell samples significantly decreased the population of 
the SMB53 genus of Clostridiaceae (0 h: 9.11 OTUs; 24 h: 2.11 OTUs; p = 0.008), 
Lachnospira and Faecalibacterium (0 h: 26.56 OTUs; 24 h: 4.44 OTUs; p = 0.008 and 0 
h 136.44 OTUs; 24 h: 66 OTUs; p = 0.022, respectively) (Table 5-3). In vivo studies with 
inulin, short-chain fructooligosaccharides and resistant starch supplementation have all 
resulted in decreases in the SMB53 genus.245,246 No genera analyzed showed significant 
increases in 24 h for the Oatwell samples measured for the three fecal donors in this 
study. The WholeFiber samples (Table 5-4) significantly increased the genus Collinsella 
at 24 h compared to 0 h (0 h: 68 OTUs; 24 h: 299.78 OTUs; p = 0.011). Bifidobacterium 
populations were only significantly increased at 24 h compared to 0 h for the XOS 
samples (0 h: 0.67 OTUs; 24 h: 5.22 OTUs; p = 0.038), while the same samples showed a 
significant decrease in Lachnospira and Faecalibacterium (p = 0.038 and p = 0.03) 
(Table 5-5). The inulin samples (Table 5-6) increased Collinsella (0 h: 55.11 OTUs; 24 h: 
291.44 OTUs; p = 0.016). The pure beta-glucan samples significantly decreased 
Lachnospira and Faecalibacterium (p = 0.008).  
 
Discussion 
The aim of this study was to investigate the beneficial effects of commonly consumed 
prebiotic dietary fibers, including their ability to influence the growth of identified 
bacterial populations, form beneficial SCFAs, and the amount of gas they produce due to 
fermentation. Total gas production due to fiber fermentation depends on a wide range of 
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factors. The inulin samples and the WholeFiber samples (mixture of dried chicory root 
inulin, pectin and hemicellulose) resulted in the highest gas production at both 12 and 24 
h. These results are consistent with results from both clinical feeding studies and other in 
vitro experiments, in which fermentation of inulin products resulted in high amounts of 
gas production, sometimes resulting in mild negative GI symptoms, depending on the 
dosage.247,248 Similar in vitro studies have found inulin to be much more fermentable than 
beta-glucan products, for both barley and oat-derived beta-glucans.249 XOS fermentation 
results in less gas production than the inulin products, and more gas than beta-glucan 
products. Because of these findings, previous studies based on digestive tolerance and 
parameters have established a tolerated daily dosage of approximately 12 g/d.250  
 
SCFA production due to the fermentation of prebiotic dietary fibers promotes many 
beneficial health outcomes to the host. SCFA production may contribute to up to 10% of 
the host’s daily metabolizable energy, with production of total SCFAs usually between 
100-200 mM/d, but is highly dependent on the donor and availability of substrates for 
fermentation.177,185 At 12 h of fermentation, the OatWell and beta-glucan samples had 
significantly higher concentrations of propionate, and the highest mean concentration at 
24 h compared to the other prebiotic dietary fibers analyzed. Similar in vitro studies with 
beta-glucan based products have also shown similar preference for these products to 
result in propionate formation.249 Although no mechanism has been identified, and 
studies show conflicting results,251 elevated serum propionate concentrations have been 
shown to have a hypocholesterolaemic effect.252 Propionate may also play an influential 
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role in satiety, although mechanisms still remain unclear.253,254 Cholesterol-lowering 
properties of beta-glucans may be limited to effects from the upper-GI, although many 
propionate-producing bacteria have a preference for fermenting various types of beta-
glucans (Bacteroides, Prevotella, Clostridium) based on the presence of genes 
responsible for endo-β-glucanase enzyme production.255  
 
Microbial diversity among fecal donors complicates the identification of trends among 
the five treatment groups (Figures 5-15 and Figure 5-16). In terms of taxonomic shift, the 
inulin-based products were fermented nearly identically by all three fecal donors. Both 
pure inulin and WholeFiber promoted the growth of Collinsella comparing the 24 h 
samples to 0 h samples. Inulin-type fructans have been shown in clinical studies to 
promote substantial growth of Collinsella, paralleled with increased urinary hippurate 
levels.256 Hippurate is a metabolite derived from various fermentation processes in the 
gut that has been found in decreased concentrations in obese individuals compared to 
lean individuals, and also between diabetics and non-diabetics.257–259 The genus 
Collinsella has been found in lower concentrations in individuals with IBD compared to 
healthy controls,260 while Collinsella aerofaciens has been associated with low risk of 
colorectal cancer.261 Increases in Collinsella and increased urinary hippurate levels are 
considered a beneficial effect of inulin consumption due to its prebiotic capacity.256  
A significant increase in the genus Bifidobacterium was observed only with the XOS 
treatment. Increases in Bifidobacterium have been heavily studied and reviewed, and are 
considered a beneficial effect due to their correlation with many positive health 
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outcomes.230 Bifidobacteria reside naturally in the gastrointestinal tract of healthy human 
adults and have a strong affinity to ferment oligosaccharides, making them a common 
marker for prebiotic capacity. Bifidobacterium is a unique genus of bacteria in that no gas 
is formed as an end product of metabolism.126 Like Lactobacillus, these bacteria are 
saccharolytic, often considered a beneficial trait.102 Bifidobacteria also do not produce 
any known carcinogenic substances in vivo. Bifidobacteria concentrations have been 
negatively associated with obesity and weight gain.127–130 Increases in Bifidobacteria 
have also been correlated with a decrease in blood lipopolysaccharides (LPS), 
inflammatory reagents that play a role in the development of inflammatory metabolic 
disorders and conditions, and are primarily found in gram-negative bacteria.262 LPS 
induce the activation of Toll-like receptor 4, which leads to inflammation due to release 
of pro-inflammatory cytokines and chemokines.263 
 
In vitro fermentations are semi-representative models of colonic fermentation, but have 
limitations.242 In vivo, formed gases are continually absorbed and colonic absorption is 
rapid. Because SCFAs are rapidly absorbed and difficult to measure, in vitro models help 
to understand the kinetics of colonic fermentation. However, in vitro models must be 
paired with similar in vivo models to better understand the full mechanisms of action 
resulting from colonic fermentation of prebiotic dietary fibers.  
 
All five prebiotics measured in this study offer specific health benefits that can be 
attributed to their fermentation. Depending on their structure, each compound offers a 
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specific carbon source for fermentation by different bacterial populations, yielding 
changes in beneficial taxa and production of various amounts of SCFAs and gas in vitro. 
For instance, while OatWell and beta-glucans promoted propionate production, XOS 
increased concentrations of Bifodobacterium, and WholeFiber and pure inulin promoted 
Collinsella growth. Findings in this study are consistent with other in vitro studies on 
similar prebiotic dietary fibers, as well as numerous clinical feeding studies. 
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Table 5-1. Comparison prebiotic dietary fibers analyzed with in vitro fermentation 
system. 
Prebiotic Dietary Fibers Supplier Information 
OatWell (Oatbran containing 28% beta-
glucan) 
DSM Nutritional Products, Ltd. 
Dried Chicory Root (containing: inulin, 
pectin, hemi/cellulose) 
WholeFiber, Inc. 
Xylooligosaccharide (XOS) AIDP, Inc. 
Pure Inulin Cargill, Inc. 
Pure Beta-glucan Megazyme, Inc. 
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Table 5-2. Demographic characteristics of three fecal donors. 
 Donor 1 Donor 2 Donor 3 
Age 26 25 22 
Sex Female Male Male 
BMI 28.1 26.3 23.0 
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Figure 5-1. Total gas production comparing fermentation differences among five prebiotic dietary fibers for three individuals at 12 h 
and 24 h post-exposure to fecal microbiota in an in vitro fermentation system. Data displayed are means (3 donors x 3 replicates = 9) 
for each prebiotic dietary fiber ± SD. Columns with different letters are significantly different from one another within each time 
measurement (lowercase: 12 h; uppercase: 24 h). Data were analyzed using ANOVA with Tukey HSD (p < 0.05).  
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Figure 5-2. Acetate production at 12 h of fermentation for five prebiotic dietary fibers 
displayed as μmol/mL of fermentation inoculum. Data displayed are means (3 donors x 3 
replicates = 9) for each prebiotic dietary fiber ± SD. Columns with different letters are 
significantly different from one another.  Data were analyzed using ANOVA with Tukey 
HSD (p < 0.05). 
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Figure 5-3. Acetate production at 24 h of fermentation for five prebiotic dietary fibers 
displayed as μmol/mL of fermentation inoculum. Data displayed are means (3 donors x 3 
replicates = 9) for each prebiotic dietary fiber ± SD. Columns with different letters are 
significantly different from one another.  Data were analyzed using ANOVA with Tukey 
HSD (p < 0.05). 
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Figure 5-4. Propionate production at 12 h of fermentation for five prebiotic dietary fibers 
displayed as μmol/mL of fermentation inoculum. Data displayed are means (3 donors x 3 
replicates = 9) for each prebiotic dietary fiber ± SD. Columns with different letters are 
significantly different from one another.  Data were analyzed using ANOVA with Tukey 
HSD (p < 0.05). 
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Figure 5-5. Propionate production at 24 h of fermentation for five prebiotic dietary fibers 
displayed as μmol/mL of fermentation inoculum. Data displayed are means (3 donors x 3 
replicates = 9) for each prebiotic dietary fiber ± SD. Columns with different letters are 
significantly different from one another.  Data were analyzed using ANOVA with Tukey 
HSD (p < 0.05). 
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Figure 5-6. Butyrate production at 12 h of fermentation for five prebiotic dietary fibers 
displayed as μmol/mL of fermentation inoculum. Data displayed are means (3 donors x 3 
replicates = 9) for each prebiotic dietary fiber ± SD. Columns with different letters are 
significantly different from one another.  Data were analyzed using ANOVA with Tukey 
HSD (p < 0.05). 
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Figure 5-7. Butyrate production at 24 h of fermentation for five prebiotic dietary fibers 
displayed as μmol/mL of fermentation inoculum. Data displayed are means (3 donors x 3 
replicates = 9) for each prebiotic dietary fiber ± SD. Columns with different letters are 
significantly different from one another.  Data were analyzed using ANOVA with Tukey 
HSD (p < 0.05). 
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Table 5-3. Combined changes across 24 h of fermentation for Oatwell samples of 
identified phyla and genera. Replicate samples were pooled among donor at each 
respective time point (3 donors x 3 replicated = 9). Samples were analyzed between 
differentially represented OTUs for significant changes after 24 h of fermentation 
compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, 
with the FDR multiple comparisons correction.  
Phyla & Genera 0 h 24 h 
Test-
Statistic P-value 
Actinobacteria     
Bifidobacterium 1.22 0.89 0.63 0.660 
Adlercreutzia 1.44 3.00 1.37 0.470 
Collinsella 48.44 140.56 6.33 0.089 
Bacteroidetes     
Alistipes 2.56 1.33 0.55 0.674 
Parabacteroides 135.00 155.89 0.05 0.952 
Bacteroides 755.67 865.00 3.95 0.192 
Firmicutes     
Eubacterium 0.44 0.56 0.20 0.817 
Veillonella 1.11 1.22 0.01 0.980 
Dorea 2.33 3.56 1.08 0.516 
Acidaminococcus 3.22 10.44 0.22 0.817 
Clostridium 7.67 8.33 0.33 0.769 
Anaerostipes 8.11 6.00 0.52 0.674 
Turicibacter 8.67 1.22 2.54 0.286 
SMB53 9.11 2.11 12.83 0.008 
Ruminococcus 11.22 23.22 3.13 0.263 
Lactococcus 11.67 10.67 0.00 0.980 
Streptococcus 15.22 8.11 1.15 0.511 
Roseburia 20.22 22.33 0.01 0.980 
Oscillospira 21.78 36.67 4.90 0.121 
Lachnospira 26.56 4.44 12.94 0.008 
Phascolarctobacterium 27.78 173.33 3.03 0.263 
Dialister 39.56 43.00 0.88 0.560 
Blautia 41.89 53.11 1.32 0.470 
Coprococcus 49.89 39.00 1.76 0.396 
Ruminococcus 61.33 40.67 2.39 0.289 
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Faecalibacterium 136.44 66.00 9.58 0.022 
Proteobacteria     
Escherichia 0.44 1.44 2.13 0.325 
Haemophilus 10.22 0.67 2.49 0.286 
Sutterella 10.78 14.44 0.00 0.980 
Bilophila 13.67 14.78 0.28 0.788 
Verrucomicrobia     
Akkermansia 5.00 12.00 0.01 0.980 
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Table 5-4. Combined changes across 24 h of fermentation for WholeFiber samples of 
identified phyla and genera. Replicate samples were pooled among donor at each 
respective time point (3 donors x 3 replicated = 9). Samples were analyzed between 
differentially represented OTUs for significant changes after 24 h of fermentation 
compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, 
with the FDR multiple comparisons correction. 
Phyla & Genera 0 h 24 h 
Test-
Statistic P-value 
Actinobacteria     
Adlercreutzia 0.89 3.89 3.61 0.239 
Bifidobacterium 1.11 1.11 0.56 0.785 
Collinsella 68.00 299.78 12.17 0.011 
Bacteroidetes     
Alistipes 1.11 0.56 0.31 0.894 
Parabacteroides 131.44 142.00 0.07 0.913 
Bacteroides 743.56 776.56 0.56 0.785 
Firmicutes     
Eubacterium 1.11 0.78 0.50 0.799 
Veillonella 1.22 1.00 0.01 0.960 
Dorea 2.00 5.00 0.66 0.785 
Acidaminococcus 2.67 11.33 0.22 0.894 
SMB53 5.67 4.00 3.58 0.239 
Clostridium 7.33 13.22 0.10 0.896 
Anaerostipes 10.22 1.22 3.60 0.239 
Ruminococcus 10.89 19.67 0.03 0.943 
Streptococcus 12.67 8.78 0.57 0.785 
Turicibacter 14.22 2.44 0.01 0.960 
Lachnospira 14.78 72.00 4.13 0.237 
Oscillospira 17.22 14.89 1.13 0.647 
Lactococcus 20.44 9.22 0.12 0.896 
Phascolarctobacterium 24.67 60.44 1.82 0.501 
Dialister 26.11 58.22 0.03 0.943 
Roseburia 28.56 6.00 0.95 0.674 
Blautia 32.44 49.44 5.08 0.156 
Coprococcus 45.78 66.44 1.64 0.501 
Ruminococcus 54.22 39.33 3.29 0.261 
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Faecalibacterium 154.89 93.11 7.75 0.080 
Proteobacteria     
Escherichia 0.78 1.44 0.00 0.960 
Sutterella 4.00 32.44 0.22 0.894 
Haemophilus 10.67 0.56 6.72 0.107 
Bilophila 10.67 7.67 0.10 0.896 
Verrucomicrobia     
Akkermansia 17.00 3.33 1.67 0.501 
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Table 5-5. Combined changes across 24 h of fermentation for xylooligosaccharide 
samples of identified phyla and genera. Replicate samples were pooled among donor at 
each respective time point (3 donors x 3 replicated = 9). Samples were analyzed between 
differentially represented OTUs for significant changes after 24 h of fermentation 
compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, 
with the FDR multiple comparisons correction.   
Phyla & Genera 0 h 24 h 
Test-
Statistic P-value 
Actinobacteria     
Bifidobacterium 0.67 5.22 9.11 0.038 
Adlercreutzia 1.33 1.78 0.08 0.972 
Collinsella 58.44 154.00 1.87 0.413 
Bacteroidetes     
Alistipes 1.44 0.56 1.85 0.413 
Parabacteroides 147.33 133.33 0.02 0.972 
Bacteroides 770.89 870.44 4.31 0.189 
Firmicutes     
Eubacterium 0.33 1.67 2.75 0.364 
Veillonella 0.67 0.00 4.78 0.162 
Acidaminococcus 1.33 2.33 0.03 0.972 
Dorea 2.11 3.67 1.70 0.423 
SMB53 7.33 5.44 1.14 0.558 
Anaerostipes 7.44 3.44 1.51 0.447 
Turicibacter 8.00 8.56 0.02 0.972 
Clostridium 8.44 4.00 6.51 0.087 
Ruminococcus 12.78 26.11 6.58 0.087 
Streptococcus 14.11 4.67 2.46 0.367 
Lachnospira 21.11 5.33 9.37 0.038 
Oscillospira 21.33 21.78 0.02 0.972 
Phascolarctobacterium 23.44 16.33 0.10 0.972 
Lactococcus 23.89 21.00 0.00 0.982 
Roseburia 28.89 35.33 0.16 0.972 
Dialister 33.89 41.56 0.42 0.831 
Blautia 39.22 65.00 6.37 0.087 
Ruminococcus 45.11 37.33 2.13 0.385 
Coprococcus 47.11 48.67 0.78 0.705 
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Faecalibacterium 148.56 79.56 11.56 0.030 
Proteobacteria     
Escherichia 0.89 0.44 0.07 0.972 
Haemophilus 6.44 3.11 0.03 0.972 
Bilophila 17.78 6.22 5.73 0.107 
Sutterella 25.78 40.89 0.43 0.831 
Verrucomicrobia     
Akkermansia 2.78 5.00 0.34 0.841 
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Table 5-6. Combined changes across 24 h of fermentation for pure inulin samples of 
identified phyla and genera. Replicate samples were pooled among donor at each 
respective time point (3 donors x 3 replicated = 9). Samples were analyzed between 
differentially represented OTUs for significant changes after 24 h of fermentation 
compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, 
with the FDR multiple comparisons correction.   
Phyla & Genera 0 h 24 h 
Test-
Statistic P-value 
Actinobacteria     
Bifidobacterium 1.33 5.44 3.94 0.304 
Adlercreutzia 1.33 2.00 0.47 0.845 
Collinsella 55.11 291.44 12.79 0.016 
Bacteroidetes     
Alistipes 1.56 0.89 0.36 0.878 
Parabacteroides 147.44 164.78 0.28 0.887 
Bacteroides 726.78 644.44 1.64 0.652 
Firmicutes     
Veillonella 0.78 0.56 0.03 0.908 
Eubacterium 0.89 1.56 0.02 0.908 
Dorea 1.78 7.00 1.96 0.640 
Acidaminococcus 3.11 18.67 0.22 0.887 
SMB53 7.44 9.11 0.00 0.965 
Turicibacter 7.78 4.89 1.06 0.652 
Clostridium 8.22 7.11 0.51 0.845 
Ruminococcus 9.56 34.11 3.61 0.309 
Anaerostipes 11.22 4.67 1.17 0.652 
Streptococcus 13.00 12.44 0.16 0.887 
Lactococcus 19.11 9.67 0.02 0.908 
Lachnospira 21.00 4.89 10.85 0.022 
Phascolarctobacterium 26.22 21.00 0.16 0.887 
Oscillospira 26.33 10.11 9.30 0.034 
Roseburia 26.78 14.11 0.28 0.887 
Dialister 32.67 95.11 0.16 0.887 
Blautia 38.22 50.22 0.86 0.690 
Coprococcus 48.11 60.89 1.88 0.640 
Ruminococcus 52.33 43.00 0.10 0.908 
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Faecalibacterium 148.11 187.33 1.22 0.652 
Proteobacteria     
Escherichia 1.00 1.22 0.04 0.908 
Haemophilus 9.11 2.67 1.45 0.652 
Sutterella 14.00 31.22 0.02 0.908 
Bilophila 16.89 7.78 3.31 0.309 
Akkermansia 7.78 7.44 4.02 0.304 
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Table 5-7. Combined changes across 24 h of fermentation for pure beta-glucan samples 
of identified phyla and genera. Replicate samples were pooled among donor at each 
respective time point (3 donors x 3 replicated = 9). Samples were analyzed between 
differentially represented OTUs for significant changes after 24 h of fermentation 
compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, 
with the FDR multiple comparisons correction.   
Phyla & Genera 0 h 24 h 
Test-
Statistic P-value 
Actinobacteria     
Bifidobacterium 0.33 0.33 0.00 1.000 
Adlercreutzia 2.00 1.89 0.07 0.843 
Collinsella 69.22 85.11 0.86 0.723 
Bacteroidetes     
Alistipes 0.78 0.89 0.32 0.778 
Parabacteroides 119.56 179.78 0.56 0.778 
Bacteroides 776.11 854.33 1.03 0.664 
Firmicutes     
Eubacterium 0.11 0.44 0.46 0.778 
Veillonella 0.56 0.22 0.38 0.778 
Dorea 0.89 3.11 7.06 0.110 
Acidaminococcus 2.33 15.11 0.22 0.778 
SMB53 6.11 4.89 0.39 0.778 
Lactococcus 6.11 0.67 0.22 0.778 
Anaerostipes 7.44 5.22 0.40 0.778 
Turicibacter 8.11 3.00 0.13 0.803 
Ruminococcus 9.44 18.67 4.35 0.166 
Clostridium 10.11 3.33 6.38 0.110 
Streptococcus 14.89 6.44 3.32 0.256 
Roseburia 16.11 54.33 1.54 0.510 
Lachnospira 21.22 3.89 12.88 0.008 
Oscillospira 24.33 35.11 2.40 0.389 
Phascolarctobacterium 29.00 125.33 3.03 0.283 
Dialister 30.56 43.67 0.10 0.819 
Coprococcus 44.11 20.78 3.79 0.211 
Blautia 45.11 68.11 2.13 0.408 
Ruminococcus 59.67 44.44 1.64 0.500 
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Faecalibacterium 152.11 62.67 12.82 0.008 
Proteobacteria     
Escherichia 0.89 0.56 0.31 0.778 
Haemophilus 11.00 0.78 5.45 0.110 
Sutterella 14.00 35.44 0.22 0.778 
Bilophila 14.44 13.89 0.20 0.778 
Verrucomicrobia     
Akkermansia 9.11 15.89 0.45 0.778 
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Figure 5-8. Identified phyla from three fecal donors microbiota at 0, 12 and 24 h of 
fermentation for five prebiotic dietary fibers analyzed based on percent of sequence 
reads.  
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Figure 5-9. Identified abundant families for three fecal donors at 0, 12 and 24 h of 
fermentation for five prebiotic dietary fibers analyzed based on percent of sequence 
reads.  
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Figure 5-10. Identified abundant genera for three fecal donors at 0, 12 and 24 h of 
fermentation for five prebiotic dietary fibers analyzed based on percent of sequence 
reads.  
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Figure 5-11. Six metrics of analysis for alpha-diversity among samples at 0, 12 and 24 h 
of analysis, grouped by donor for all five prebiotic dietary fibers analyzed.  
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Figure 5-12. Six metrics of analysis for alpha-diversity among samples at 0, 12 and 24 h 
of analysis, grouped by treatment for all three fecal donors.  
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Figure 5-13.  Bray-Curtis β-diversity principal component analysis of technical replicates 
among each treatment group between microbiota analysis of three fecal donors.  
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Figure 5-14. Bray-Curtis β-diversity principal component analysis among microbiota of 
three fecal donors at 0, 12 and 24 h of analysis.  
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Figure 5-15. Variations in abundant phyla among three donors analyzed. 
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Figure 5-16. Variations in treatment groups and pooled donors analyzed. 
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CHAPTER SIX 
Organic Fertility Treatment Effects on Shortfall Nutrients and Nitrate Accumulation in 
Leafy Greens  
Executive Summary  
Arugula (Eruca sativa), mizuna (Brassica rapa var. nipponsinca), red giant mustard 
(Brassica juncea) and spinach (Spinacia oleracea ‘Tyee’) are fresh produce crops high in 
nutritive value that provide shortfall and high interest nutrients addressed in the 2015 
U.S. Dietary Guidelines.264,265 The primary objective of this project was to evaluate 
fertility treatments unique to these crops that optimize their nutritional capacity. 
Measurements discussed include: vitamin C, dietary fiber, calcium, iron, potassium, 
sodium and nitrate. Plants were grown at the University of Minnesota St. Paul Campus 
(St. Paul, MN) in a greenhouse from November to April under an 18 h photoperiod and a 
24/13C day/night temperature. Plants were grown using five different fertility treatments, 
including four organic treatments and one conventional control. The plant treatment 
combinations were replicated three times and the entire experiment was duplicated. 
Fertility treatments had a high impact on vitamin C (with over a 3-fold difference in 
treatments in the first experiment), nitrate (over 10-fold difference among fertility 
treatments in some species) and potassium concentrations (over 5-fold difference among 
fertility treatments in some species) in analyzed plant tissue. No consistent differences 
were found for fiber, calcium, iron and sodium concentrations in tissue analyzed. This is 
the first study to analyze the impact that different organic treatments can have on multiple 
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deficient nutrients and compounds addressed by the U.S. Dietary Guidelines for high-
impact, highly-consumed produce crops. 
 
Introduction  
Consuming fresh produce offers a healthy way to introduce many shortfall nutrients into 
the diet of the consumer, while increasing their intake of wholesome, nutrient-dense 
foods.266 The 2015 U.S. Dietary Guidelines suggests increasing vegetable intake, 
specifically green salad vegetables, as these are consumed in low quantities and have 
been associated with many health outcomes.267 Arugula (Eruca sativa), mizuna (Brassica 
rapa var. nipposinica) and red giant mustard (Brassica juncea) are Mesclun mixture 
plants that are nutrient-dense and consumed in many regions.268 Spinach (Spinacia 
oleracea) is commonly consumed as both a plate vegetable and salad green, and has 
quintupled in consumption since the early 1970’s, with nearly 60% of current 
consumption coming from fresh-market spinach.269 
 
Organic crops are produced in systems that do not utilize synthetic fertilizer, pesticides 
and growth regulators, and rely heavily on animal and plant manures and biological pest 
control for successful growth of crops.270 Key fundamentals of traditional organic 
production encourage long-term fertility of soils, minimization of carbon footprints and 
maintenance of genetic diversity in current food systems.271 In greenhouse systems in 
enclosed environments, key organic practices can be implemented, like the use of non-
synthetic fertilizers and pesticides, although are not complete replacements of traditional 
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organic practices in an open field environment. Differences in organically and 
conventional produced foods have been extensively reviewed, based on their nutritive 
value, sensory qualities and overall safety.272 
 
Minerals play many critical roles in human physiology, and are responsible for a wide 
range of activities in the body. In plants, iron plays a critical role as a cofactor in 
chloroplast biosynthesis.273 Calcium is known for its ability to aid in the formation of 
stable cell walls and membranes, and regulates stimulus of cells.274,275 Potassium 
primarily acts as a cofactor for protein synthesis and is a major solute in maintaining 
water balance and osmosis.275 In the human body, iron aids in oxygen and electron 
transport, DNA synthesis and many other critical roles.276 Calcium aids in bone formation 
and higher intake has been associated with higher rates of whole-body fat oxidation.277 
Potassium intake has been associated with protective effects against hypertension.278  
 
In plants, vitamin C acts as a substrate for ascorbic acid peroxidase,279,280  plays a 
fundamental role in photosynthesis,281 acts as an enzyme cofactor in the synthesis of 
anthocyanins and ethylene282 and helps keep alpha-tocopherol in a reduced state.283 In the 
human body, vitamin C plays many roles, including the ability to act as a water-soluble 
antioxidant, aids in collagen synthesis, increases absorption of iron from the diet and 
plays other critical roles in the metabolism of folate and some amino acids.284 
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Dietary fiber is a critical shortfall nutrient in the United States. The typical U.S. 
individual consumes 17 g/d while the current Dietary Recommended Intake (DRI) is 25 
g/d for adult women and 38 g/d for adult men, respectively.140,141 The DRI is based on 
decreased risk for developing cardiovascular disease19, but fiber has also been shown to 
decrease the risk for developing type 2 diabetes when more than 15 g/d285 is consumed, 
increase satiety,286 promote weight loss37 and provide many other beneficial 
effects.6,287,288 
 
Nitrate is generally considered safe to consume in moderate amounts, and is easily 
converted to nitrite through reduction.289 Although nitrate and nitrite are not carcinogenic 
themselves, they can easily yield carcinogenic compounds. Nitrates react with secondary 
and tertiary amines endogenously, forming N-nitroso compounds.289 N-nitroso 
compounds have been associated with higher risk of developing esophagus, stomach and 
liver carcinomas.290–292 Nitrate accumulation is common in Brassica plants as well as 
other leafy vegetables such as spinach and lettuce, and is influenced heavily by nitrogen 
fertilization practices.293  
 
Under the new FDA Nutrition & Supplements Facts Label Rule (2016), foods with 
nutrition facts panel will now be required to label potassium (a new addition) along with 
calcium and iron (previously required). The Daily Values (DV) for sodium decreased 
(2400 mg to 2300 mg), and increased for potassium (3500 mg to 4700 mg), calcium 
(1000 mg to 1300 mg) and dietary fiber (25 g to 28 g).294 With these changes, 
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requirements for nutrient content claims will also be affected, changing the levels 
required in the product to make an “excellent source” or “good source” claim for any of 
these nutrients. Understanding the factors that influence concentrations of these key 
nutrients in produce is critical, especially as manufacturers reformulate nutrition facts 
panels and consumers are interested in new nutrient labels.  
 
The purpose of this project was to address differences in shortfall nutrients and nutrients 
of interest in arugula, red giant mustard, mizuna and spinach and how they differ among 
organic nutrient amendments along with a conventional comparison. These four plants 
were chosen because they have a high nutrient density, are frequently consumed in many 
populations and have high amounts of common shortfall nutrients.  
 
Materials and Methods 
Plants 
Arugula (Eruca sativa), mizuna (Brassica rapa var. nipponsinca), red giant mustard 
(Brassica juncea) and spinach (Spinacia oleracea ‘Tyee’) were grown on five different 
fertilizer/media combinations.  All seed for this study was obtained from Johnny’s 
Selected Seeds (Winslow, ME). 
 
Arugula, mizuna, and red giant mustard seeds were sown into standard 1020 trays (28 cm 
x 54 cm x 6 cm) at a density of 11 mg per tray.  Spinach was sown into 50 cell deep plug 
trays with two seeds per cell, plants were thinned to one plant per cell after germination.  
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All four species were grown on all five fertilizer/media combinations and replicated three 
times. The entire experiment was completed twice.   
Fertility Treatments 
Media and fertility treatments (Table 6-1) were mixed prior to planting.  Fertility was 
scaled to meet field nitrogen requirements for crops on low organic matter soils 
according to University of Minnesota Extension materials.295 Treatments were fertilized 
by converting the recommended kg N/ha to kg N/m3 using a depth of 15 cm, then 
calculating the weight of solid fertilizer or volume of liquid fertilizer to apply to the 
volume of media in each container using the guaranteed analysis of each fertilizer 
product.  Both the custom mix and all-in-one potting mix exceeded nitrogen 
recommendations and so were not further amended. Full nitrogen recommendation was 
112 kg/ha for leafy greens. Bulk densities of the compared media ranged from 0.086 - 
0.307 g/cm3 for the treatment groups (Table 6-2).  Chemical analysis of media nutrients 
was conducted for complete comparison of soil nutrients (Table 6-3). Greens were grown 
to baby leaf lettuce size, and so did not require the second application.  
 
Plant Harvest 
All plants were grown on benches in a greenhouse (on campus) maintained with a 24°C 
day temperature and 13°C night temperature. Benches were blocked by treatment. Greens 
were harvested when the majority of leaves were 10 cm long by cutting with scissors. 
Greens were harvested between 1 to 3 times depending on plant vigor. All plant tissue 
and soil data were taken at time of first harvest.  Harvest occurred between 4 and 9 weeks 
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after planting. Tissue samples for vitamin C and dietary fiber analysis were frozen 
immediately at -80°C. Tissue samples for mineral analysis were dried to completion at 
60°C, and crosschecked to control for moisture removal completion.  
Plants (Table 6-8) were also grown at three greenhouses in Minnesota that participated as 
volunteers in this study in order to provide comparisons to plants grown on campus. 
Growers were provided with packets of detailed instructions for the experiment and 
provided with all required materials. Regular visits were scheduled with research staff to 
ensure compliance and conduct analysis.  
 
Media and Tissue Analysis 
Exchangeable calcium was extracted from the media by mixing 10 mL or 1N, pH7, 
ammonium acetate with 10 g of air-dried sample, and then placed in a shaker for 5 
minutes. The filtered extract was analyzed with an inductively coupled plasma atomc 
(DTPA) emission spectrometer (ICP-AES). Extractable iron was determined by treating a 
10 g sample of air-dried media with 20 mL of diethylenetriamine-pentaacetic acid 
(DTPA) extracting solution. Samples were placed in a shaker for 2 h, and then filtered an 
analyzed with an ICP-AES for iron concentration of media. Available potassium was 
extracted from the media by mixing 10 mL of 1N ammonium acetate, pH7, with 1 g of 
air-dried media and then placed in a shaker for 5 minutes. Available potassium was then 
measured by analyzing the filtered extract on an ICP-AES set on emission mode at 776 
nm. Nitrate-nitrogen was determined by adding 60 mL of KCl extracting solution to a 2 g 
sample of air-dried media, and then placed in a shaker for 15 minutes. The nitrate level in 
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the filtered extract was measured on a Lachat QuckChem 8500 Flow Injection Analyzer 
by the cadmium reduction method. Bulk densities of media were calculated according to 
Grafton et al with minor revisions.296 Plant tissue minerals (calcium, iron, potassium and 
sodium) were analyzed by weighing 500 mg of air-dried tissue into a 20 mL high form 
silica crucible and dry ashed at 485°C for 12 h (covered). Ash was then equilibrated with 
5 mL of 20% HCl at room temperature for 30 minutes, followed by an addition of 5 mL 
of deionized water, then allowed to settle for 3 hours prior to ICP-AES analysis. Plant 
tissue nitrate nitrogen was extracted by shaking 300 mg of dried sample with 30 mL 0.1 
m CaSO4 solution for 30 minutes, followed by the addition of 0.85 cc of prewashed 
charcoal, followed by shaking for an additional 5 minutes. Samples were filtered through 
Whatman (No. 42) filter paper and nitrate concentrations in the filtrate were determined 
colorimetrically by the cadmium reduction method.  
 
Vitamin C and Fiber Quantitation 
Vitamin C was quantified using the AOAC 967.22 method from 50 g samples of frozen  
(-80°C) plant tissue. Total dietary fiber was quantified using the AOAC 991.43 method 
from 100 g samples of frozen (-80°C) plant tissue.  
 
Statistical Analysis 
All statistical analysis was conducted using SPSS (SPSS Chicago, IL). Analysis of 
variance (ANOVA) with Tukey HSD was used for all tests measuring differences among 
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means. Log transformations were applied where necessary based on regression fit. 
Statistical significance was achieved for p-values less than 0.05. 
 
Comparison of Plants Grown in Experiment 1 and Experiment 2 
ANOVA indicated that there were significant differences between experiment 1 and 
experiment 2 for fertility treatment interactions (p<0.001), so biomass, nitrate and 
nutrient levels were analyzed separately for each experiment.  
 
Results and Discussion  
Harvested Biomass 
Harvested biomass for arugula varied among the five treatments in experiment 1 (Figure 
6-1). CM had the highest harvested biomass (598.5 g/m2), which was significantly more 
than the FE treatment (330.7 g/m2; p=0.039). The CM, AO, CC and PL treatments 
produced similar results. In experiment 2, the CC and CM treatments resulted in 
significantly greater harvested biomass than the AO, FE and PL treatments (p<0.01).  
The harvested biomass for mizuna (Figure 6-2) in experiment 1 varied among treatments, 
and also varied from experiment 2. In experiment 1, the CM, CC, FE and PL treatments 
all had similar harvested weights, and the AO treatment was significantly greater than the 
other four treatments (1719.6 g/m2; p<0.001). In experiment 2, the CM treatment yielded 
a higher harvest biomass than the other four treatments (2087 g/m2; p<0.01).  
The harvested biomass for red giant mustard (Figure 6-3) was highest in experiment 1 for 
the AO treatment (1314.3 g/m2) and was significantly higher than all other treatments in 
   134
experiment 1 (p<0.002). The CC, FE and PL treatments were all statistically similar to 
one another, while the CM treatment was the significantly lower than these three 
treatments (303.6 g/m2; p<0.01). In experiment 2 the CM treatment had the highest 
harvested biomass (1747.3 g/m2) and was statistically similar to the AO treatment 
(1435.2 g/m2; p=0.22) and the CC treatment (1343.2 g/m2; p=0.081). The PL treatment 
had the lowest harvested biomass (205.0g/m2) and was significantly lower than all other 
treatments (p<0.001).  
 
Harvested spinach biomass for experiment 1 (Figure 6-4) differed among treatments. The 
AO treatment (1161.5 g/m2) was similar to the CC treatment (834.6 g/m2; p=0.392), but 
significantly higher than the CM, FE and PL treatments (p<0.05). The CM treatment had 
the lowest overall harvested biomass (418.6 g/m2), but was statistically similar to the CC, 
FE and PL treatments. In experiment 2, the AO resulted in the highest overall harvested 
biomass (1494.1 g/m2) and was statistically similar to the CM treatment (1195.8 g/m2; 
p=0.376) and the CC treatment (996.4 g/m2; p=0.058).  
 
Minerals 
In experiment 1, the mineral concentration in the harvested plants varied greatly among 
treatments and species (Table 6-4). For red giant mustard, there was no difference 
between iron, potassium and sodium concentrations. For calcium, the CC treatment had 
the highest concentration (191.3 mg/100 g fw), which was statistically higher than the 
CM treatment (138.2 mg/100g fw; p=0.031), while the FE, AO and PL treatments were 
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all similar. For the mizuna plants the potassium and sodium concentrations were most 
affected by the treatments. The CM treatment (860.3 mg/100g fw) was significantly 
higher than the CC (393.1 mg/100g fw), FE (120.16 mg/100g fw) and PL (164.39 
mg/100g fw) treatments for measured potassium (p<0.001). Sodium concentrations were 
also greatly affected by the treatments in the mizuna plants with nearly a 10-fold 
difference between the CM treatment (14.25 mg/100g fw) and the FE treatment (142.66 
mg/100g fw; p<0.001). Arugula iron concentrations were unaffected by the fertility 
treatments. Arugula potassium varied greatly among the treatments, most notably with 
the CM treatment having the highest concentration (950.7 mg/100g fw; p<0.001). In 
spinach, concentrations of calcium, iron and sodium were unaffected by the fertility 
treatments, although the CC treatment was over 3-fold higher in potassium (995.12 
mg/100g fw) than the FE treatment (287.43 mg/100g fw; p<0.001). Statistical relations 
between the collected soil and tissue mineral data in experiment 1 showed a significant 
correlation between potassium concentrations in the collected mizuna plants and soil at 
time of harvest (p=0.028), and a positive correlation for mizuna and red giant mustard 
(soil mineral data only collected for experiment 1). 
 
In experiment 2, mineral concentrations followed some similar trends compared to 
experiment 1 (Table 6-5). For red giant mustard plants, iron was not affected by the 
fertility treatments. Potassium concentrations varied greatly, with the largest difference 
between the CM treatment (696.31 mg/100g fw) and the PL treatment (98.86 mg/100g 
fw; p<0.001). For the mizuna plants the iron also was not affected by the fertility 
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treatments, but the potassium concentration was over 8-fold higher in the CM treatment 
(666.67 mg/100g fw) compared to the FE treatment (81.49 mg/100g fw; p<0.001). For 
arugula, calcium concentrations were similar among all treatments, while there was over 
a 5-fold difference between the CM and FE potassium concentrations. The spinach iron 
concentrations were similar for all the treatments, while the FE treatment resulted in the 
highest sodium concentration compared to the other treatments (261.86 mg/100g fw; 
p<0.001).  
 
Nutrient content claims can play a significant role in consumer perception of a product, 
and a consumers willingness to buy a product.297 Under the new FDA requirements for 
labeling, the minimum requirement of calcium in a product needed to make a “good 
source” nutrient content claim is 130 mg per 100 g serving (10% of 1300 mg required by 
DV), nearly all of the plants under all the fertility treatments would qualify from both 
experiments. For potassium, a “good source” claim would require a minimum of 470 mg 
per 100 g serving. This claim could only be made for the CM and AO treatments (based 
on averages from both experiments) in the red giant mustard, mizuna and arugula plants. 
The use of different fertility treatments affects potassium and could have a significant 
impact on product sales and consumer preferences as new nutrient content claims and 
nutrition facts panels are made for these products. The FE treatment produced the highest 
average sodium concentrations in all plants analyzed in experiment 1 and 2 (with the 
exception of arugula in experiment 2). As a publicized nutrient of concern with a 
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decreasing DV, produce grown with similar FE treatments might produce less marketable 
products to consumers.  
 
Vitamin C 
Vitamin C is a highly unstable water-soluble vitamin known for its antioxidant 
properties, both in humans and plants. Key effects on vitamin C concentration include the 
growing conditions, plant stage at harvest, storage temperature and wide range of 
postharvest conditions.298,299 Traditionally, accumulation of vitamin C is increased 
whenever plants are exposed to high oxidative stress, including full sunlight, low nitrogen 
availability in the soil and drought conditions.300 For fresh produce, vitamin C losses can 
be enhanced when postharvest storage is extended, or at higher temperature, low relative 
humidity and freezing.298 High nitrogen fertilizers have also been associated with 
decreased vitamin C concentrations in many fruits and vegetables.298  
Mizuna vitamin C was analyzed for all five fertility treatments in experiment 1 and for 
four fertility treatments for experiment 2. In experiment 1, the PL treatment had the 
highest average vitamin C concentration (16.1 mg), but was statistically similar to all 
other treatments, except for the CM treatment (p = 0.002) (Figure 6-5). In experiment 2, 
the CC treatment had the highest concentration (48.13 mg) compared to all other 
treatments (p<0.001) (Figure 6-5). CM had a higher concentration than FE (16.86 mg; 
p=0.018) and AO (16.03 mg; p=0.008). Between experiments, fertility treatments 
resulted in a wide fluctuation in mizuna vitamin C concentrations, with all treatment 
averages lower in the first experiment. For the CC treatment, the average for experiment 
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1 was 11.94mg/100 g whereas in experiment 2 it was 48.13 mg/100 g. Because many pre-
harvest factors (genotypic, climatic and environmental) influence vitamin C, variation 
between experiments and growing seasons is common.301  
In experiment 1, the red giant mustard PL treatment had the highest mean vitamin C 
concentration (21.26 mg), but was statistically similar to the CC treatment (15.7 mg; 
p=0.116) (Figure 6-6). The PL treatment had significantly higher concentrations than the 
FE treatment (14.03 mg; p=0.049), AO treatment (12.48 mg; p=0.022) and CM treatment 
(8.45 mg; p=0.022). In experiment 2 (Figure 6-4), the CC treatment (32.4 mg) had similar 
concentrations to the FE treatment (27.53 mg; p=0.369), the AO treatment (43.23 mg; 
p=0.067) and CM treatment (23.36 mg; p=0.115). 
 
Fiber 
Dietary fiber is a mixture of complex organic substances that are non-digestible in the 
upper gastrointestinal tract, present as both soluble and insoluble compounds. Studies 
have analyzed dietary fiber differences between conventionally and organically grown 
plums, with little differences observed.302 To our knowledge, dietary fiber has not been 
analyzed in nutrient dense crops that address shortfall nutrients, comparing either organic 
or conventional nutrient sources.   
 
For mizuna plants in experiment 1 (Figure 6-7), the CC treatment (2.94 g) had 
statistically similar concentrations of total dietary fiber compared to the PL treatment 
(3.24 g; p=0.051) and also to the FE treatment (3.06 g; p=0.367). Both the CM treatment 
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(2.04 g) and the AO treatment (1.82 g) had similar total dietary fiber concentrations, 
p<0.001 and p<0.001, respectively. In experiment 2, the CC treatment (4.30 g) had 
significantly higher total dietary fiber than the CM treatment (2.47 g; p<0.001) and lower 
than the AO treatment (3.77 g; p=0.02) and the FE treatment (4.96 g; p=0.007).  
 
For red giant mustard plants in experiment 1 (Figure 6-8), the CC treatment (2.88 g) had 
statistically similar concentrations to the PL treatment (2.86 g; p=0.868), while the CM 
treatment (2.03 g; p<0.001), the FE treatment (2.20 g; p<0.001) and AO treatment (1.44 
g; p<0.001) were all significantly less than the CC treatment. In experiment 2, the CC 
treatment (4.79 g) was statistically similar to both the FE treatment (4.65 g; p=0.588) and 
the AO treatment (4.32 g; p=0.091), but was greater than the CM treatment (2.01 g; 
p<0.001) in total dietary fiber concentration.   
 
Under the 2016 FDA Nutrition & Supplements Facts Label Revisions, the new DV for 
dietary fiber is increasing to 28 g/d. Based on this new rule, 2.8 g fiber/serving will be 
required to make a “good source” nutrient content claim. Based on the combined 
averages from both experiments, only the mizuna and red giant mustard with the CC and 
FE treatments would qualify for this claim. Based on a single experiment, the mizuna and 
red giant mustard with the PL treatment would also qualify. Products labeled as a “good 
source of fiber” have been perceived as being slightly healthier to consumers, and are 
often more marketable products.297   
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Nitrate (NO3-N) 
Nitrate-N concentrations varied greatly among treatments, species and experiments 
(Table 6-6). Compared to the four other treatments, the CM treatment had significantly 
higher nitrate-N concentrations for all the analyzed plants (p<0.01). For the arugula in 
experiment 1, the CM treatment (1244 ppm [mg/kg fresh weight]) and the AO treatment 
(1255 ppm) were significantly higher than the other three treatments (p<0.001). In the 
mizuna plants, the CM (1443 ppm) and AO (1656 ppm) treatments were significantly 
higher than the other treatments (p<0.001). In experiment 2, the arugula had the same 
nitrate-N concentration for the CC, FE and PL treatments, while the CM treatment (734 
ppm) was significantly higher than the rest (p<0.001). For the spinach, mizuna and red 
giant mustard plants analyzed in experiment 2, the CM treatment had the highest nitrate-
N concentration (p<0.001). Statistical analyses between the soil nitrate-N concentrations 
(taken at first harvest) and plant tissue nitrate-N concentrations showed a significant 
correlation (p<0.05) for arugula, mizuna and red giant mustard plants analyzed from 
Experiment 1 (Table 7), showing that high nitrate-N in soil leads to high nitrate-N in 
harvested plant tissue. 
 
For nearly half of the produce analyzed in this study, an average consumer (68 kg) would 
exceed their recommended daily nitrate intake with only two servings (100 g/serving) of 
produce. The European Food Safety Authority (EFSA) and The World Health 
Association (WHO) recommend that daily nitrate intake is below 3.7 mg dietary nitrate/ 
lb of body weight, as expressed by the Acceptable Daily Intake (ADI). (When converted 
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from nitrate to NO3-N as used in this study [multiplying by 0.22] this would be equal to a 
recommendation 130 mg, or less, of calculated NO3-N for a 160 lb individual). 
Vegetables are the number one source of nitrates in the diet for many populations, so 
monitoring intake is crucial to minimize the potentially harmful effects of high nitrate 
diets.303,304  
 
Careful considerations need to be made when applying nitrogen to both conventional and 
organic plants, as excessive nitrogen yields excessive amounts of nitrate accumulation in 
plant tissues. Both organic and conventional produce can have excessive amounts of 
nitrates, depending on growing and environmental conditions.  
 
Comparison Plants from Commercial Opeations 
Red giant mustard and mizuna plants were collected from three growers and greenhouses 
in Minnesota for nutrient and nitrate comparisons to campus-grown plants throughout 
experiment 1 and experiment 2 (Table 6-8). For the red giant mustard, the vitamin C 
concentrations in experiment 2 nearly all fell within  range of the comparison produce, 
while experiment 1 was slightly lower. Calcium levels in the comparison produce were 
higher than both experiment 1 and 2 for red giant mustard. For mizuna, experiment 1 had 
slightly lower vitamin C concentrations than the comparison produce, while experiment 2 
had similar concentrations. Similar to red giant mustard, the mizuna plants also had much 
lower calcium concentrations in experiment 1 and 2 (128 – 251 mg/100g) compared to 
the comparison mizuna (229-422 mg/100g). Nitrate levels varied greatly for both red 
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giant mustard and mizuna plants, similar to experiment 1 and 2. The average 
concentration in the comparison red giant mustard was 1599 ppm, which was less than 
the CM and AO treatments in experiment 1, but greater than all other analyzed red giant 
mustard plants. The comparison mizuna had an average concentration of 1175 ppm, 
which was only less than the CM and AO treatments in experiment 1, and greater than all 
other analyzed mizuna plants, which was the same trend for both species of plants.  
 
Conclusions 
For the arugula, red giant mustard, mizuna and spinach plants evaluated in these 
experiments, significant differences in iron, potassium, calcium, sodium, vitamin C and 
fiber found among the fertility treatments were dependent on the experiment. Depending 
on the season in which the plants are grown, this can result in changes in any of these 
shortfall nutrients or nutrients of high interest. For all treatments in both experiments, for 
both mizuna and red giant mustard plants, plants harvested in experiment 2 had 
significantly higher vitamin C concentrations than in experiment 1 (p<0.001). For 
vitamin C, concentrations in plants are dependent on the plants exposure to oxidative 
stress, and are also dependent on the amount of available nitrogen. Fluctuations in 
vitamin C concentrations between experiments was most likely due to changes in sunlight 
exposure, as the plants in experiment 2 were grown in early spring, whereas plants grown 
in experiment 1 were grown during the winter months. Among all the combined samples 
analyzed, the CC treatment had the highest vitamin C concentrations (p=0.02) compared 
to the other treatments, and equal or higher calcium concentrations in those plants, 
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although only in experiment 1. Calcium concentrations were most likely higher in the CC 
treatment plants because the CC treatment had the second highest calcium concentration 
out of all the experimental media.  
 
Careful considerations need to be made when choosing fertility treatments for produce 
items that could be marketed with nutrient content claims, or labeled with nutrition facts 
panels. These values have been shown to influence consumers and therefore they could 
have potential positive or negative influences on consumer preference. Because the FDA 
will now require potassium to be labeled on nutrition facts panels, and because it is 
heavily influenced by the fertility treatment, growers will have to choose fertility 
treatments carefully in the future to maximize potassium concentrations in produce. 
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Table 6-1. Fertility Treatment Combinations of Media and Fertility Sources. 
Treatment Media Base Fertilizer 
All-in-One Potting Mix (AO) Purple Cow Organic Potting 
Mix (Purple Cow Organics, 
Middleton, WI) 
None 
Custom Mix (CM) Peat, vermiculite, leaf litter 
compost (3:2:3 mix by 
volume) 
 Greensand, rock phosphate, 
bloodmeal and lime. 
(1:1:1:0.5 mix by volume) 
Conventional Comparison 
(CC) 
SunGro LC8 (SunGro 
Horticulture, Agawam, MA) 
Peter’s Excel CalMag 15-5-
15 (Everris, Dublin, OH) 
Fish Emulsion (FE) Sunshine Natural and Organic 
Planting Mix (SunGro 
Horticulture, Agawam, MA) 
Dramatic 2-5-0.2 (Dramm, 
Manitowoc, WI) 
Poultry Litter (PL) Sunshine Natural and Organic 
Planting Mix (SunGro 
Horticulture, Agawam, MA) 
SUSTANE 8-4-4 (Sustane, 
Cannon Falls, MN) 
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Table 6-2. Bulk Densities of Compared Media 
Treatment Bulk Density 
(g/cm3) 
All-in-One Potting Mix (AO) 0.307 
Custom Mix (CM) 0.181 
Conventional Comparison (CC) 0.138 
Fish Emulsion (FE) 0.086 
Poultry Litter (PL) 0.086 
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Table 6-3. Soil Nutrient Profile Comparisons For Five Fertility Treatments Analyzed.  
 CC AO CM FE PL 
 Mineral data below as mg/kg dry soil 
pH 5.90 
(0.20) 
6.75 
(0.25) 
6.40 
(0.08)* 
6.15 
(0.05) 
6.25 
(0.05) 
Soluble 
Salts 
(dS/m)  
3.08 
(0.50) 
3.57 
(1.05) 
10.20  
(1.18)* 
1.78 
(0.27) 
1.39 
(0.27) 
NO3-N 
 
3734  
(714) 
3617  
(2410) 
1492 
 (1418)* 
1010 
 (5.44) 
Below 
detection 
limit 
NH4-N 225(32) 13.74 (5.16) 352 (106)* 
433 
 (26) 
223 (71) 
P 141 (13) 346 (27) 110 (15)* 614 (39) 140 (31) 
K 1099 (157) 2970 (123) 10330 (684)* 421 (62) 457 (131) 
Fe 3.23 
(0.23) 
1.59 
(0.20) 
3.62 
(0.94)* 
2.15 
(0)** 
1.23 
(0)** 
Ca 2051 (167) 1462 (117) 2333 (221)* 1155 (78) 928 (102) 
Mg 1675 (69) 754 (120) 715 (62)* 1180 (175) 906 (124) 
B 1.01 
(0.15) 
2.89 
(0.25) 
4.43 
(0.60)* 
Below 
detection 
limit 
Below 
detection 
limit 
Na 182 (10) 635 (24) 215 (16)* 674 (100) 279 (40) 
Mn 5.60 (2.6) 2.70 (1.1) 7.38 (1.2)* 2.89 (0.26) 2.43 (0.26) 
Mo 0.21 
(0)** 
0.22 
(0.04) 
0.22 
(.08) 
Below 
detection 
limit 
0.25 
(0)** 
Zn 1.90 (0.24) 0.5 (0.07) 0.67 (0.05)* 0.72 (0) 0.59 (0.15) 
Data shown are mean (SD). Data shown are n=2 unless otherwise noted (*n=3, **n=1).  
Conventional Control (CC); All-in-One Potting Mix (AO); Custom Mix (CM); Fish 
Emulsion (FE); Poultry Litter (PL).
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Table 6-4. Mineral Comparison Among Fertility Treatments (mg/100 g fresh weight) – 
Experiment 1  
 
  Fertility Treatment 
Mineral CC  CM  FE  AO  PL  
 
 
Red 
Giant 
Mustard 
Ca 191.3 b 138.2 a 166.1 a,b 188.3 a,b 189.4 a,b 
Fe 1.1 0.7 1.1 0.7 1.2 
K 416 600.54 347.93 813.76 262.60 
Na 32.3 43.7 144.9 55.9 75.8 
 
 
 
Mizuna 
Ca 239.3 b 128.9 a 201.6 b 229.6 b 205.9 b 
Fe 0.6 a 0.9 b 0.6 a 0.8 a,b 0.7 a 
K 393.1 b 860.2 c 120.1 a 750.4 c 164.4 a 
Na 26.4 a 14.3 a 142.7 d 70.7 b 105.2 c 
 
 
 
Arugula 
Ca 200.9 b 130.7 a,b 154.62 a,b 187.8 a,b 112.9 a 
Fe 0.9 0.8 0.8 0.7 0.9 
K 455.3 b 950.7 d 309.0 a,b 662.7 c 277.6 a 
Na 26.6 a 10.8 a 113.7 b 31.4 a 60.7 a,b 
 
 
 
Spinach 
Ca 83.9 * 144.3 * 76.3 
Fe 0.8 * 0.9 * 0.8 
K 995.1 b * 287.4 a * 820.2 b 
Na 42.8 * 137.9 * 92.1 
 
Data shown are mean (n=3) for each respective species. Results analyzed using ANOVA 
Tukey HSD for significance testing (p<0.05). Significance analyzed for each species 
within each experiment. * Indicates missing samples due to space capacity of experiment 
in greenhouse. 
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Table 6-5. Mineral Comparison Among Fertility Treatments (mg/100g fresh weight) – 
Experiment 2 Results 
 
  Fertility Treatment 
Mineral CC  CM  FE  AO  PL  
 
 
Red 
Giant 
Mustard 
Ca 154.1 a 191.8 b 139.7 a 144.6 a 134.1 a 
Fe 0.6 0.7 0.5 0.6 0.9 
K 130.9 a 696.3 c 104.6 a 388.6 b 98.9 a 
Na 41.2 b,c 16.5 a 75.7 d 29.7 a,b 50 c 
 
 
 
Mizuna 
Ca 176.0 a 215.2 b 258.3 c 177.8 a 251.8 b,c 
Fe 0.5 0.7 0.3 0.4 1.1 
K 134.6 a 666.7 c 81.5 a 464.7 b 107.1 a 
Na 28.7 a,b 16.2 a 58.4 c 30.2 b 57.5 b,c 
 
 
 
Arugula 
Ca 162.2 193.1 153.1 N/A 164.9 
Fe 0.6 b,c 0.7 c 0.5 a,b N/A 0.5 a 
K 315.8 b,c 642.2 c 122.8 a N/A 155.1 a,b 
Na 35.1 b 14.8 a 44.1 b N/A 45.8 b 
 
 
 
Spinach 
Ca 94.9 c 88.3 b,c 71.2 a,b 62.6 a 66.9 a 
Fe 0.6 0.6 0.7 0.6 0.5 
K 332.9 a 1201.9 b 229.4 a 1147.1 b 285.6 a 
Na 119.8 c 20.3 a 261.9 e 60.2 b 184.8 d 
Data shown are mean (n=3) for each respective species. Results analyzed using ANOVA 
Tukey HSD for significance testing (p<0.05). Significance analyzed for each species 
within each experiment. 
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Table 6-6. Nitrate-N Concentrations (NO3-N ppm; mg/kg fresh weight) in Arugula, Spinach, Mizuna and Red Giant Mustard for 
Experiment 1 and Experiment 2.  
  Fertility Treatments 
  CC  CM  FE  AO  PL  
 
 
 
Experiment 1 
Arugula 266 a 
 
1244 b 218 a 1255 b 100 a 
Spinach 1988 b 
 
N/A 1236 a,b N/A 932 a 
Mizuna 171 a 
 
1443 b 20 a 1656 b 12 a 
Red Giant 
Mustard 
171 a 1673 b 194 a 2279 c 21 a 
 
 
 
Experiment 
2 
Arugula 5 a 
 
734 b 4 a N/A 6 a 
Spinach 587  c 
 
1251 d 241 a,b 473 b,c 48 a 
Mizuna 3 a 
 
614 b < 1 a 2 a < 1 a 
Red Giant 
Mustard 
19 a 877 b 3 a 16 a 3 a 
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Table 6-7. Soil Nitrate-N Concentrations (NO3-N ppm; mg/kg dry weight) Correlated to 
Plant Tissue Nitrate-N Concentrations (NO3-N ppm; mg/kg fresh weight) in Arugula, 
Mizuna and Red Giant Mustard in Experiment 1.  
 Pearson’s  r p 
Arugula 0.813 <0.001 
Mizuna 0.539 0.047 
Red Giant Mustard 0.723 0.002 
 
Statistical relations were determined with bivariate correlations (Pearson’s r), and a p < 
0.05 was accepted as statistically significant. Correlations were made between soil and 
tissue Nitrate-N concentrations for each individual plant species.  
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Table 6-8. Conventionally Grown Produce Collected Throughout Both Experiments From Three Minnesota Growers and 
Greenhouses.  
 Vitamin C 
(mg/100g) 
Fiber 
(g/100g) 
Ca 
(mg/100g) 
Fe 
(mg/100g) 
K 
(mg/100g) 
Na 
(mg/100g) 
Nitrate-N 
(ppm) 
Red Giant 
Mustard 
Mean 
Median 
Range 
 
31.73 
29 
 
20.4-45.8 
 
3.81 
3.5 
2.19-5.74 
 
251.6 
254.3 
254-331 
 
0.76 
0.79 
0.64-0.83 
 
558.3 
585.5 
486-602 
 
48.9 
42.8 
33-71 
 
1599 
2218 
59.7-2520 
Mizuna 
Mean 
Median 
Range 
 
28.6 
23.4 
16.6-45.8 
 
3.65 
3.5 
2.13-5.34 
 
294.8 
232.3 
229-422 
 
0.87 
0.93 
0.72-0.97 
 
482.9 
492.6 
395-560 
 
42.1 
38.4 
36-51 
 
1175 
1577 
70-1878 
*Data displayed are three triplicate samples from three different greenhouses and growers.
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Figure 6-1. Comparison of Arugula Harvested Biomass Among Treatments in 
Experiment 1 and Experiment 2. 
 
 
Data shown are mean ± standard deviation for two different replicate experiments. 
Significant differences among mean values are indicated with different letters above bars 
(p<0.05) with lower-case letters for experiment 1 and capital letters for experiment 2. 
Results analyzed using ANOVA Tukey HSD for significance testing. 
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Figure 6-2. Comparison of Mizuna Harvested Biomass Among Treatments in Experiment 
1 and Experiment 2. 
 
Data shown are mean ± standard deviation for two different replicate experiments. 
Significant differences among mean values are indicated with different letters above bars 
(p<0.05) with lower-case letters for experiment 1 and capital letters for experiment 2. 
Results analyzed using ANOVA Tukey HSD for significance testing. 
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Figure 6-3. Comparison of Red Giant Mustard Harvested Biomass Among Treatments in 
Experiment 1 and Experiment 2. 
 
Data shown are mean ± standard deviation for two different replicate experiments. 
Significant differences among mean values are indicated with different letters above bars 
(p<0.05) with lower-case letters for experiment 1 and capital letters for experiment 2. 
Results analyzed using ANOVA Tukey HSD for significance testing. 
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Figure 6-4. Comparison of Spinach Harvested Biomass Among Treatments in 
Experiment 1 and Experiment 2. 
 
Data shown are mean ± standard deviation for two different replicate experiments. 
Significant differences among mean values are indicated with different letters above bars 
(p<0.05) with lower-case letters for experiment 1 and capital letters for experiment 2. 
Results analyzed using ANOVA Tukey HSD for significance testing. 
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Figure 6-5. Mizuna Vitamin C Concentration (mg/100g Fresh Weight) in Harvested 
Biomass – Experiment 1 and Experiment 2. 
 
Data shown are mean ± standard deviation for two different replicate experiments. 
Significant differences among mean values are indicated with different letters above bars 
(p<0.05) with lower-case letters for experiment 1 and capital letters for experiment 2. 
Results analyzed using ANOVA Tukey HSD for significance testing. 
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Figure 6-6. Red Giant Mustard Vitamin C Concentration (mg/100g Fresh Weight) in 
Harvested Biomass – Experiment 1 and Experiment 2.  
 
Data shown are mean ± standard deviation for two different replicate experiments. 
Significant differences among mean values are indicated with different letters above bars 
(p<0.05) with lower-case letters for experiment 1 and capital letters for experiment 2. 
Results analyzed using ANOVA Tukey HSD for significance testing. 
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Figure 6-7. Total Dietary Fiber in Mizuna (g/100g Fresh Weight) Determined with 
AOAC 991.43.  
 
Data shown are mean ± standard deviation for two different replicate experiments. 
Significant differences among mean values are indicated with different letters above bars 
(p<0.05) with lower-case letters for experiment 1 and capital letters for experiment 2. 
Results analyzed using ANOVA Tukey HSD for significance testing. 
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Figure 6-8. Total Dietary Fiber in Red Giant Mustard (g/100g Fresh Weight) Determined 
with AOAC 991.43. 
 
Data shown are mean ± standard deviation for two different replicate experiments. 
Significant differences among mean values are indicated with different letters above bars 
(p<0.05) with lower-case letters for experiment 1 and capital letters for experiment 2. 
Results analyzed using ANOVA Tukey HSD for significance testing. 
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Appendix 
 
Summary and Contribution to the Field  
 
Prebiotic dietary fibers play a critical role in helping develop and maintain a healthy gut 
microbiome and improving digestive health. Because of their ability to ferment as a 
primary carbon source for beneficial taxa, prebiotics have the long-term potential to 
improve the gut microbiome. In vitro models provide mechanistic fermentation kinetics, 
laying the foundation for clinical feeding studies to further elucidate the health impacts 
that the fermentation of these compounds may have.  
 
Key scientific contributions made as a part of these studies included the finding of 
partially hydrolyzed guar gum (PHGG) to increase the beneficial genera of 
Parabacteriodes, a key bacteria that has been shown in clinical studies to be inversely 
associated with irritable bowel syndrome (IBS) symptoms and disease. Previous to our 
findings, PHGG was known to be therapeutic for individuals affected with IBS, but this 
was for unknown reasons. In follow-up studies, our research was able to show that there 
can be over a 2-fold difference in SCFA production, potentially the contributing factor 
for why some people find PHGG consumption therapeutic, and others may not. This is 
hypothesized to be due to the differences in the gut microbiota between individuals, but 
with our small samples size, we were unable to determine any significant correlations 
between these differences in donors.  Our experimental results supported our initial 
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hypothesis that PHGG was a readily fermentable fiber, provided a substantial amount of 
SCFA production, and provided growth to potentially therapeutic taxa.  
 
All of the dietary fibers analyzed in this study are emerging prebiotics in that limited 
studies have been conducted to show their prebiotic capacity. Our studies were able to 
show that PHGG and wheat dextrin promote lactogenic and bifidogenic growth within 12 
h of exposure, which was previously unknown. Of all the dietary fibers measured, the 
xylooligosaccharide fiber was the most bifidogenic fiber, and is the most effective 
prebiotic dietary fiber in that regard. Although these compounds promote the growth of 
beneficial bacteria in vitro, in still remains unknown if they have the same potential in 
clinical studies over longer durations. Future studies building on these findings should 
investigate the ability of these compounds to promote host health as part of a diverse, 
long-term diet. Studies should be formulated testing the hypotheses that 
xylooligosaccharides promote the growth of Bifidobacteria as part of a well-balanced, 
healthy diet in vivo, and that all the compounds included in these studies would still 
provide beneficial amounts of SCFAs when consumed daily as part of a healthy diet and 
lifestyle.  
 
Investigating the effects that fertility treatments can have on nitrate accumulation and 
nutrients in produce grown in Minnesota is critical in determining the safety and 
effectiveness of these treatments. Our study was unique in that it examined the effects of 
fertility treatments currently being used in Minnesota by many growers. Based on these 
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findings, nitrate accumulation in the analyzed plants may be above recommended values, 
primarily due to excess nitrogen in the fertility treatments. Because of the differences in 
experiments, it is still unknown if certain fertility treatments can have consistent 
influences on the levels of minerals and vitamins in the harvested plants.  Future studies 
should be formulated to test the hypothesis that certain organic fertility treatments can 
result in produce higher in nutritive value, with nitrate values in the harvested tissue in 
acceptable ranges for consumer health.  
 
 
